Table of Contents


UNITEDSTATES

SECURITIES ANDEXCHANGECOMMISSION

Washington, D.C. 20549

 


FORM10-Q


(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 20172018

 

OR

 

TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934

 

For the transition period _____ to_____.

Commission file number: 000-50644

 


Cutera,Inc.

(Exact name of registrant as specified in its charter)


 

Delaware

(Stateorotherjurisdictionofincorporationororganization)

77-0492262

(State or other jurisdiction of incorporation or organization)

(I.R.S.employeridentificationno.)

 

3240BayshoreBlvd.,Brisbane,California94005

(Addressofprincipalexecutiveoffices)

 

(415)657-5500

(Registrant’s Registrant’stelephonenumber,includingareacode)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing

requirements for the past 90 days.    Yes    No   

 

Indicate by check mark whether the registrantregistrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such

shorter period that the registrant was required to submit and post such files). Yes No   

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. SeeSee definitions of “large accelerated filer,” “accelerated filer” and, “smaller reporting company”  and "emerging growth company" in Rule 12b-2 of the Exchange Act (check one):

 

Large accelerated filer  ☐

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

Accelerated filer  ☒

Non-accelerated filer  ☐

Smaller reporting company  ☐

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes    No   

 

The number ofRegistrant had 13,836,800 shares of Registrant’s common stock, issued and$0.001 par value per share, outstanding as of July 31, 2017 was 14,005,063.2018.

 


 

Table of Contents

 

CUTERA, INC.

 

FORM 10-Q

 

TABLEOFCONTENTS

Page

PART I

FINANCIAL INFORMATION

Page

PART I

FINANCIAL INFORMATION

Item 1

Financial Statements (unaudited)

3

 

Condensed Consolidated Balance Sheets

3

 

Condensed Consolidated Statements of Operations

4

 

Condensed Consolidated Statements of Comprehensive Income (Loss)

5

 

Condensed Consolidated Statements of Cash Flows

6

 

Notes to Condensed Consolidated Financial Statements

7

Item 2

Management’sManagement’s Discussion and Analysis of Financial Condition and Results of Operations

1421

Item 3

Quantitative and Qualitative Disclosures About Market Risk

21

29

Item 4

Controls and Procedures

2230

PART II

OTHER INFORMATION

Item 1

Legal Proceedings

Legal Proceedings

2331

Item 1A

Risk Factors

Risk Factors

2331

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

2431

Item 3

Defaults Upon Senior Securities

2431

Item 4

Mine Safety Disclosures

2431

Item 5

Other Information

Other Information

2431

Item 6

Exhibits

Exhibits

2532

 

Signature

Signature

2532

 


2

Table of Contents

 

PART I. FINANCIAL INFORMATION

 

ITEM

ITEM1.FINANCIALSTATEMENTS

FINANCIAL STATEMENTS

 

CUTERA,INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(inthousands,, except share and per share data)except

(unaudited)shareandpersharedata)

  

June 30, 2017

  

December 31, 2016

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $18,679  $13,775 

Marketable investments

  32,270   40,299 

Restricted investments

  2,290    

Accounts receivable, net

  18,191   16,547 

Inventories

  16,913   14,977 

Other current assets and prepaid expenses

  2,840   2,251 

Total current assets

  91,183   87,849 
         

Property and equipment, net

  1,867   1,907 

Deferred tax asset

  381   377 

Intangibles, net

     2 

Goodwill

  1,339   1,339 

Other long-term assets

  381   380 

Total assets

 $95,151  $91,854 
         

Liabilities and Stockholders' Equity

        

Current liabilities:

        

Accounts payable

 $4,293  $2,598 

Accrued liabilities

  18,973   17,397 

Deferred revenue

  8,901   8,394 

Total current liabilities

  32,167   28,389 
         

Deferred revenue, net of current portion

  1,982   1,705 

Income tax liability

  170   168 

Other long-term liabilities

  604   582 

Total liabilities

  34,923   30,844 
         

Commitments and Contingencies (Note 10)

        
         

Stockholders’ equity:

        

Convertible preferred stock, $0.001 par value; authorized: 5,000,000 shares; none issued and outstanding

      

Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 14,003,583 and 13,773,389 shares at June 30, 2017 and December 31, 2016, respectively

  14   14 

Additional paid-in capital

  86,403   88,114 

Accumulated deficit

  (26,121

)

  (27,046

)

Accumulated other comprehensive loss

  (68

)

  (72

)

Total stockholders’ equity

  60,228   61,010 
         

Total liabilities and stockholders’ equity

 $95,151  $91,854 


The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.(unaudited)

 


  

June 30, 2018

  

December 31, 2017

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $18,432  $14,184 

Marketable investments

  10,573   21,728 

Accounts receivable, net

  22,122   20,777 

Inventories

  30,138   28,782 

Other current assets and prepaid expenses

  3,469   2,903 

Total current assets

  84,734   88,374 
         

Property and equipment, net

  2,632   2,096 

Deferred tax asset

  21,219   19,055 

Goodwill

  1,339   1,339 

Other long-term assets

  5,807   374 

Total assets

 $115,731  $111,238 
         

Liabilities and Stockholders' Equity

        

Current liabilities:

        

Accounts payable

 $10,743  $7,002 

Accrued liabilities

  22,756   26,848 

Deferred revenue

  9,288   9,461 

Total current liabilities

  42,787   43,311 
         

Deferred revenue, net of current portion

  2,519   2,195 

Income tax liability

  386   379 

Other long-term liabilities

  665   460 

Total liabilities

  46,357   46,345 
         

Commitments and Contingencies (Note 14)

        
         

Stockholders’ equity:

        

Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 13,824,252 and 13,477,973 shares at June 30, 2018 and December 31, 2017, respectively

  14   13 

Additional paid-in capital

  66,291   62,025 

Accumulated deficit

  3,156   2,947 

Accumulated other comprehensive loss

  (87)   (92)

 

Total stockholders’ equity

  69,374   64,893 
         

Total liabilities and stockholders’ equity

 $115,731  $111,238 

CUTERA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2017

  

2016

  

2017

  

2016

 

Net revenue:

                

Products

 $31,727  $22,454  $56,202  $40,410 

Service

  4,662   5,023   9,486   9,490 

Total net revenue

  36,389   27,477   65,688   49,900 

Cost of revenue:

                

Products

  13,840   8,996   24,984   16,644 

Service

  1,503   2,476   4,137   4,777 

Total cost of revenue

  15,343   11,472   29,121   21,421 

Gross profit

  21,046   16,005   36,567   28,479 
                 

Operating expenses:

                

Sales and marketing

  12,787   10,712   23,560   19,428 

Research and development

  2,981   2,712   5,926   5,421 

General and administrative

  3,548   3,997   6,764   7,217 

Total operating expenses

  19,316   17,421   36,250   32,066 

Income (loss) from operations

  1,730   (1,416

)

  317   (3,587

)

Interest and other income, net

  276   217   549   361 

Income (loss) before income taxes

  2,006   (1,199

)

  866   (3,226

)

Provision (benefit) for income taxes

  59   30   (59

)

  54 

Net income (loss)

 $1,947  $(1,229

)

 $925  $(3,280

)

                 

Net income (loss) per share:

                

Basic

 $0.14  $(0.09

)

 $0.07  $(0.25

)

Diluted

 $0.13  $(0.09

)

 $0.06  $(0.25

)

                 

Weighted-average number of shares used in per share calculations:

                

Basic

  13,935   13,131   13,888   13,071 

Diluted

  14,629   13,131   14,633   13,071 

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

 


3

Table of Contents

 

CUTERA, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)OPERATIONS

(in thousands)thousands, except per share data)

 (unaudited)

 

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2017

  

2016

  

2017

  

2016

 

Net income (loss)

 $1,947  $(1,229

)

 $925  $(3,280

)

Other comprehensive income (loss):

                

Available-for-sale investments

                

Net change in unrealized gain on available-for-sale investments

  5   11   8   80 

Less: Reclassification adjustment for gains on investments recognized during the period

        (4

)

   

Net change in unrealized gain on available-for-sale investments

  5   11   4   80 

Tax provision

     29      29 

Other comprehensive income (loss), net of tax

  5   (18

)

  4   51 

Comprehensive income (loss)

 $1,952  $(1,247

)

 $929  $(3,229

)

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2018

  

2017

  

2018

  

2017

 

Net revenue:

                

Products

 $37,650  $31,727  $66,914  $56,202 

Service

  4,903   4,662   9,764   9,486 

Total net revenue

  42,553   36,389   76,678   65,688 

Cost of revenue:

                

Products

  17,045   13,840   30,967   24,984 

Service

  3,131   1,503   6,000   4,137 

Total cost of revenue

  20,176   15,343   36,967   29,121 

Gross profit

  22,377   21,046   39,711   36,567 
                 

Operating expenses:

                

Sales and marketing

  15,535   12,787   28,623   23,560 

Research and development

  4,095   2,981   7,651   5,926 

General and administrative

  4,902   3,548   10,341   6,764 

Total operating expenses

  24,532   19,316   46,615   36,250 

Income (loss) from operations

  (2,155)   1,730   (6,904)   317 

Interest and other income (expense), net

  (129)   276   (31)   549 

Income (loss) before income taxes

  (2,284)   2,006   (6,935)   866 

Provision (benefit) for income taxes

  (712)   59   (3,331)   (59) 

Net income (loss)

 $(1,572)  $1,947  $(3,604)  $925 
                 

Net income (loss) per share:

                

Basic

 $(0.11)  $0.14  $(0.26)  $0.07 

Diluted

 $(0.11)  $0.13  $(0.26)  $0.06 
                 

Weighted-average number of shares used in per share calculations:

                

Basic

  13,709   13,935   13,649   13,888 

Diluted

  13,709   14,629   13,649   14,633 

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

 


4

Table of Contents

 

CUTERA, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSCOMPREHENSIVE INCOME (LOSS)

(inthousands)

(in thousands)

(unaudited)

 

  

Six Months Ended June 30,

 
  

2017

  

2016

 

Cash flows from operating activities:

        

Net income (loss)

 $925  $(3,280

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

        

Stock-based compensation

  2,626   2,082 

Depreciation and amortization

  492   484 

Other

  (45

)

  (63

)

Changes in assets and liabilities:

        

Accounts receivable

  (1,641

)

  464 

Inventories

  (1,936

)

  (2,624

)

Other current assets and prepaid expenses

  (545

)

  (861

)

Other long-term assets

  (1

)

  (64

)

Accounts payable

  1,695   793 

Accrued liabilities

  1,534   (773

)

Other long-term liabilities

     (164

)

Deferred revenue

  784   (321

)

Income tax liability

  2   (25

)

Net cash provided by (used) in operating activities

  3,890   (4,352

)

         

Cash flows from investing activities:

        

Acquisition of property, equipment and software

  (210

)

  (137

)

Disposal of property and equipment

  40   6 

Proceeds from sales of marketable investments

  6,754   5,051 

Proceeds from maturities of marketable investments

  24,812   10,585 

Purchase of marketable investments

  (25,863

)

  (14,003

)

Net cash provided by investing activities

  5,533   1,502 
         

Cash flows from financing activities:

        

Repurchase of common stock

  (7,041

)

  (2,865

)

Proceeds from exercise of stock options and employee stock purchase plan

  3,871   2,950 

Taxes paid related to net share settlement of equity awards

  (1,167

)

  (556

)

Payments on capital lease obligations

  (182

)

  (127

)

Net cash used in financing activities

  (4,519

)

  (598

)

         

Net increase (decrease) in cash and cash equivalents

  4,904   (3,448

)

Cash and cash equivalents at beginning of period

  13,775   10,868 

Cash and cash equivalents at end of period

 $18,679  $7,420 
         

Supplemental disclosure of non-cash items:

        

Repurchase of common stock acquired but not settled

 $  $84 

Assets acquired under capital lease

 $257  $365 

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2018

  

2017

  

2018

  

2017

 

Net income (loss)

 $(1,572) $1,947  $(3,604)  $925 

Other comprehensive income (loss):

                

Available-for-sale investments

                

Net change in unrealized gains (losses) on available-for-sale investments

  18   5   (4)   8 

Less: Reclassification adjustment for gains (losses) on investments recognized during the period

        9   (4)

 

Net change in unrealized gains and losses on available-for-sale investments

  18   5   5   4 

Tax provision

            

Other comprehensive income (loss), net of tax

  18   5   5   4 

Comprehensive income (loss)

 $(1,554) $1,952  $(3,599)  $929 

 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

 


5

CUTERA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(inthousands)

(unaudited)

  

Six Months Ended June 30,

 
  

2018

  

2017

 

Cash flows from operating activities:

        

Net income (loss)

 $(3,604)  $925 

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

        

Stock-based compensation

  3,893   2,626 

Depreciation of tangible assets

  544   492 

Amortization of contract acquisition costs

  822    

Change in deferred tax assets

  (3,324)    
    Provision for doubtful accounts receivable  487   (3) 

Other

  (25)   (42) 

Changes in assets and liabilities:

        

Accounts receivable

  (1,832)   (1,641)

 

Inventories

  (1,356)   (1,936)

 

Other current assets and prepaid expenses

  (569)   (545) 

Other long-term assets

  (1,578)   (1) 

Accounts payable

  3,741   1,695 

Accrued liabilities

  (4,325)   1,534 

Other long-term liabilities

  70    

Deferred revenue

  546   784 

Income tax liability

  7   2 

Net cash provided by (used in) operating activities

  (6,503)   3,890 
         

Cash flows from investing activities:

        

Acquisition of property, equipment and software

  (581)

 

  (210) 

Disposal of property and equipment

  38   40 

Proceeds from sales of marketable investments

  13,044   6,754 

Proceeds from maturities of marketable investments

  2,500   24,812 

Purchase of marketable investments

  (4,390)   (25,863) 

Net cash provided by investing activities

  10,611   5,533 
         

Cash flows from financing activities:

        

Repurchase of common stock

     (7,041)

 

Proceeds from exercise of stock options and employee stock purchase plan

  3,038   3,871 

Taxes paid related to net share settlement of equity awards

  (2,664)   (1,167)

 

Payments on capital lease obligations

  (234)   (182)

 

Net cash provided by (used) in financing activities

  140   (4,519)

 

         

Net increase in cash and cash equivalents

  4,248   4,904 

Cash and cash equivalents at beginning of period

  14,184   13,775 

Cash and cash equivalents at end of period

 $18,432  $18,679 
         

Supplemental disclosure of non-cash items:

        

Assets acquired under capital lease

 $533  $257 

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

6

 

CUTERA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note1.SummaryofSignificantAccountingPolicies

 

Description of Operations and Principles of Consolidation

Cutera, Inc. (“Cutera®(“Cutera” or the “Company”) is a global provider of laser and other energy-based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, and markets laser and other energy-based product platforms for use by physicians and other qualified practitioners which enable them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following key system platforms: enlighten®,excel V, excel HR, enlighten, Juliet, Secret RF, truSculpt ®, truSculpt®, excel V®,and xeo®. The Company’s systems offer multiple hand pieces and applications, which allow customers to upgrade their systems. The sales of (i) systems, system upgrades and hand pieces (“Systems” revenue); (ii) hand piece refills (refills applicable to Titan, truSculpt 3D ®and truSculpt iD), as well as single use disposable tips applicable to Juliet, Secret RF (“Consumables” revenue); and (iii) the distribution of third party manufactured skincare products ("Skincare” revenue); and are collectively classified as “Products” revenue. In addition to Products revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan, truSculpt 3D and truSculpt iD) and service labor for the repair and maintenance of products that are out of warranty, all of which is classified as “Service” revenue.

 

Headquartered in Brisbane, California, the Company has wholly-owned subsidiariessubsidiaries that are currently operational in Australia, Belgium, Canada, France, Germany, Hong Kong, Japan, Spain, Switzerland and the United Kingdom. These subsidiaries market, sell and service the Company’s products outside of the United States. The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All inter-company accounts, transactions and balances have been eliminated.

 

Unaudited Interim Financial Information

The interimIn the opinion of the Company, the accompanying unaudited condensed consolidated financial information filed is unaudited. The Condensed Consolidated Financial Statementsstatements included in this report reflect all adjustments (consisting of only of normal recurring adjustments) that the Company considers necessary for thea fair statement of theits financial position as of June 30, 2018, its results of operations for the interimthree and six months periods coveredended June 30, 2018, and of2017, comprehensive income (loss) for the financial condition ofthree and six months periods ended June 30, 2018 and 2017, and cash flows for the Company at the date of the interim balance sheet.six months ended June 30, 2018, and 2017. The December 31, 2016 Condensed Consolidated Balance Sheet2017 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statementsaccompanying condensed consolidated financial statements should be read in conjunction with the Company’s previously filed audited financial statements and the related notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 20162017 filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2017.26, 2018.

 

Use of Estimates

The preparation of interim Condensed Consolidated Financial Statements in conformity with GAAP requires the Company’sCompany’s management to make estimates and assumptions that affect the amounts reported of assets and disclosed inliabilities and disclosure of contingent assets and liabilities at the Condensed Consolidated Financialdate of the condensed consolidated financial Statements and the accompanying notes. These estimates are based on management's best knowledgenotes, and the reported amounts of current eventsrevenue and actions we may undertake inexpenses during the future. reported periods. Actual results could differ materially from those estimates.

On an ongoing basis, the Company evaluates thesetheir estimates, including those related to revenue elements, warranty obligations,obligation, sales commissions,commission, accounts receivable and sales allowances, provision for excess and obsoletevaluation of inventories, fair values of marketable investments, fair values of acquired intangible assets,goodwill, useful lives of intangible assets and property and equipment, assumptions regarding variables used in calculating the fair valuesvalue of the Company's equity awards, expected achievement of performance stock unitsbased vesting criteria, fair value of investments, the standalone selling price of the Company's products and optionsservices, the customer life and period of benefit used to purchase the Company’s stock,capitalize and amortize contracts acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, legal matters and claims, and effective income tax rates, among others. Management bases thesetheir estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Risks and Uncertainties

 

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, stability of world financial markets, cybersecurity breaches and other disruptions that could compromise the Company’s information or results, management of international activities, competition from substitute products and larger companies, ability to obtain regulatory approval, government regulations, patent and other litigations, ability to protect proprietary technology from counterfeit versions of the Company's products, strategic relationships and dependence on key individuals. If the Company fails to adhere to ongoing Food and Drug Administration (the "FDA") Quality System Regulation, the FDA may withdraw its market clearance or take other action. The Company's manufacturers and suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA's Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede the Company's ability to meet demand.

RecentComparability

The Company adopted the new revenue standard effective January 1, 2018, using the modified retrospective method. Prior period financial statements were not retrospectively restated. The consolidated balance sheet as of December 31, 2017 and results of operations for the three and six months ended June 30, 2017 were prepared using an accounting standard that was different than that in effect for the three and six months ended June 30, 2018. As a result the consolidated balance sheets as of June 30, 2018 and December 31, 2017 are not directly comparable, nor are the condensed consolidated statement of operations for the three and six months ended June 30, 2018 and June 30, 2017.

Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("(“FASB”), jointly with the International issued Accounting Standards Board, issued a comprehensive new standard onUpdate (“ASU”) 2014-09, “Revenue from Contracts with Customers,” amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard's core principleamended guidance, herein referred to as Topic 606, is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying this new guidance to contracts within its scope, an entity will: (1) identify the contract(s) with a customer, (2) identify the performance obligation in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Additionally, this new guidance would require significantly expanded disclosures about revenue recognition. Provisions of this new standard are effective for annual reporting periods (includingand interim reporting periods within thosebeginning after December 15, 2017, with early adoption permitted for public companies effective for annual periods)and interim reporting periods beginning after December 15, 2016. The Company adopted the new revenue standard in the first quarter of fiscal year 2018 using the modified retrospective method. The Company recognized the cumulative effect of applying the new revenue standard as an adjustment to retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented.

See Note 2 – Revenue Recognition, for additional accounting policy and transition disclosures.

Other Accounting Pronouncements Not Yet Adopted

In April 2015,June 2018, the FASB proposed a deferralissued ASU No. 2018-07, "Compensation –Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting". The new guidance changes the accounting for nonemployee awards including: (1) Equity-classified share-based payment awards issued to nonemployees will be measured on the grant date, instead of this standard'sthe previous requirement to remeasure the awards through the performance completion date, (2) For performance conditions, compensation cost associated with the award will be recognized when the achievement of the performance condition is probable, rather than upon achievement of the performance condition, and (3) The current requirement to reassess the classification (equity or liability) for nonemployee awards upon vesting will be eliminated, except for awards in the form of convertible instruments. The new guidance also clarifies that any share-based payment awards issued to customers should be evaluated under ASC 606. The amendments in the new guidance are effective date by one year. The proposed deferral allowsfor annual and interim reporting periods beginning after December 15, 2018, with early adoption atpermitted for public companies, but no earlier than an entity’s adoption date of Topic 606. The Company will adopt the originalnew standard effective date. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance.

January 1, 2019. The Company is still currently evaluating the effectsimpact of adopting the new guidance and have not yet selected a transition method or determined the potential effects of adoption on the consolidated financial statements.standard.


 

In February 2016, the FASB issued ASU No. 2016-02, Leases. This guidance establishes a right-of-use (“ROU”) model that"Leases" (Topic 842), which amends the existing accounting standards for leases. The new standard requires a lesseelessees to record a ROUright-of-use asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases). The new standard also requires expanded disclosures regarding leasing arrangements. The new standard becomes effective for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognitionCompany in the Consolidated Statementfirst quarter of Operations.fiscal year 2019 and early adoption is permitted. The mandatory adoption date of thisnew standard is for fiscal years beginning after December 15, 2018. Arequired to be adopted using the modified retrospective transition approach is required for leases existingand requires application of the new standard at or entered into, after the beginning of the earliest comparative period presented inpresented. The Company finances its fleet of vehicles used by its field sales and service employees and has facility leases. Several of the financial statements,Company’s customers finance purchases of its system products through third party lease companies and not directly with certain practical expedients available.the Company. The Company does not believe that the new standard will change customer buying patterns or behaviors for its products. The Company will adopt the new standard effective January 1, 2019. The Company expects that upon adoption, ROUright-of-use assets and lease liabilities will be recognized in the balance sheet in amounts that will be material.

Note 2. Revenue recognition

 

The Company adopted ASC Topic 606, "Revenue from Contracts with Customers," on January 1, 2018, applying the modified retrospective method to all contract agreements that were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. A cumulative catch up adjustment was recorded to beginning retained earnings to reflect the impact of all existing arrangements under Topic 606.

Upon adoption of the Topic 606, the Company recorded an increase to retained earnings, net of deferred tax liability of $3.8 million (Note 12) for contracts still in force as of January 1, 2018 for the following items in the first and second quarters of 2018:

$237,000 reduction in deferred revenue balances for the differences in the amount of revenue recognition for the Company’s revenue streams as a result of allocation of revenue based on standalone selling prices to the Company’s various performance obligations.

$151,000 increase in deferred revenue balances, related to the accretion of financing costs for multi-year post-warranty service contracts for customers who pay more than one year in advance of receiving the service. The Company estimated interest expense for such advance payments under the new revenue standard.

$210,000 for variable consideration on sale transactions.

$4.7 million for the capitalization of the incremental contract acquisition costs, such as sales commissions paid in connection with system sales. These contract acquisition costs were capitalized and will be amortized over the period of anticipated support renewals. The Company expensed such costs when incurred under the prior guidance.

●  $1.2 million deferred tax liability related to the direct tax effect of the ASC 606 adoption. 

The Company’s revenue consists of product and service revenue resulting from the sale of systems, training on the systems, extended service contracts, consumables and other accessories. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods or services are transferred to the Company’s customers, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company's system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s system sale arrangements include a combination of the following performance obligations: The System and software license (considered as one performance obligation), system accessories (hand pieces), training, other accessories, extended service contracts and marketing services. For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services (which are satisfied over time), the Company generally satisfies all of the performance obligations at a point in time. Systems, system accessories (hand pieces), training, and time and material services are also sold on a stand-alone basis.

The following table summarizes the effects of adopting Topic 606 on the Company’s condensed consolidated balance sheet as of June 30, 2018:

  

As reported under

Topic 606

  

Adjustments

  

Balances under

Prior GAAP

 
  

(In thousands)

 
             

Other long-term assets

 $5,807  $5,325  $482 
Deferred tax asset  21,219   (1,160)   22,379 

Accrued liabilities

  22,756   (111)   22,867 

Deferred revenue

  11,807   (255)   11,552 

Retained earnings (deficit)

  3,156   4,530   (1,374) 

The following table summarizes the effects of adopting Topic 606 on the Company’s condensed consolidated income statement for the three months ended June 30, 2018:

  

As reported under

Topic 606

  Adjustments  

Balances under

Prior GAAP

 
             
  (In thousands) 

Products revenue

 $37,650  $55  $37,595 

Service revenue

  4,903   69   4,834 

Sales and marketing

  15,535   (463)   15,998 

Interest and other income, net*

  (129)   (64)   (65) 

The following table summarizes the effects of adopting Topic 606 on Company’s condensed consolidated income statement for the six months ended June 30, 2018:

  

As reported under

Topic 606

  Adjustments  Balances under Prior GAAP 
             
  (In thousands) 

Products revenue

 $66,914  $65  $66,849 

Service revenue

  9,764   133   9,631 

Sales and marketing

  28,623   (648)  29,271 

Interest and other income, net*

  (31)  (129)  98 

* Included in interest and other income, net, is the estimated interest expense for advance payment related to service contracts under the new revenue standard.

Adoption of the standard had no impact on total net cash from or used in operating, investing, or financing activities within the condensed consolidated statements of cash flows.

As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; (iii) not to recast revenue for contracts that begin and end in the same fiscal year; and (iv) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

Note 2. Cash,N Cashote 3 Equivalents. Cash, Cash Equivalent andMarketable Investments

 

The Company invests its cash primarily in money market funds and in highly liquid debt instruments of U.S. federal and municipal governments and their agencies, commercial paper and corporate notes and bonds, municipal bonds, and debt securities issued by the U.S. government and its agencies. The Company considerssecurities. All highly liquid investments with stated maturities of three months or less from date of purchase are classified as cash equivalents; all highly liquid investments with an original maturity of three months or less at the time of purchase, to be cash equivalents. Investments withstated maturities of greater than three months are classified as marketable investments. The majority of the Company’s cash and investments are held in U.S. banks and its foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short term operating expenses.

The Company determines the appropriate classification of its investments in marketable securities at the time of purchase areand re-evaluates such designation at each balance sheet date. The Company’s marketable securities have been classified and accounted for as “available-for-sale,”available-for-sale securities. Investments with remaining maturities of more than one year are viewed by the Company as available to support current operations, and are classified as current assets under the caption marketable investments in the accompanying condensed consolidated balance sheets. Investments in marketable securities are carried at fair value, with the unrealized gains and losses reported as a component of stockholders’ equity,equity. Any realized gains or losses on the sale of marketable securities are held for use in current operationsdetermined on a specific identification method, and such gains and losses are classified in current assets as “marketable investments.” Marketable investments that were collateralized for a standby letter of credit, were reflected as "restricted investments."a component of interest and other income, net.

 

The following tablestables summarize the components, and the unrealized gains and losses position, related to the Company’s cash, cash equivalents marketable investments and restrictedmarketable investments (in thousands): as of June 30, 2018 and December 31, 2017:

 

June 30, 2017

 

Amortized

Cost

  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  

Fair Market

Value

 

June 30, 2018

 

Amortized

Cost

  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  

Fair Market

Value

 

Cash and cash equivalents:

                                

Cash

 $11,604  $  $  $11,604  $15,545  $  $  $15,545 

Money market funds

  982         982   2,887         2,887 

Commercial paper

  6,093         6,093 

Total cash and cash equivalents

  18,679         18,679   18,432         18,432 
                                

Marketable investments:

                                

U.S. government notes

  2,861      (6

)

  2,855   6,012      (8

)

  6,004 

U.S. government agencies

  2,005      (1

)

  2,004 

Municipal securities

  200         200   200      (1

)

  199 

Commercial paper

  14,319   2   (1

)

  14,320 

Corporate debt securities

  12,891   8   (8

)

  12,891   4,388      (18

)

  4,370 

Total marketable investments

  32,276   10   (16

)

  32,270   10,600      (27

)

  10,573 
                                

Restricted investments:

                

Money market funds

  25         25 

U.S. government notes

  2,266      (1

)

  2,265 

Total restricted investments

  2,291      (1

)

  2,290 
                

Total cash, cash equivalents, marketable investments and restricted investments

 $53,246  $10  $(17

)

 $53,239 

Total cash, cash equivalents and marketable investments

 $29,032  $  $(27

)

 $29,005 

 

December 31, 2016

 

Amortized

Cost

  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  

Fair Market

Value

 

Cash and cash equivalents:

                

Cash

 $6,672  $  $  $6,672 

Money market funds

  6,053         6,053 

Commercial paper

  1,050         1,050 

Total cash and cash equivalents

  13,775         13,775 
                 

Marketable investments:

                

U.S. government notes

  8,403   4   (9

)

  8,398 

U.S. government agencies

  3,918      (2

)

  3,916 

Municipal securities

  1,325         1,325 

Commercial paper

  12,299   2   (2

)

  12,299 

Corporate debt securities

  14,366   3   (8

)

  14,361 

Total marketable investments

  40,311   9   (21

)

  40,299 
                 

Total cash, cash equivalents and marketable investments

 $54,086  $9  $(21

)

 $54,074 

December 31, 2017

 

Amortized

Cost

  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  

Fair Market

Value

 

Cash and cash equivalents:

                

Cash

 $14,058  $  $  $14,058 

Money market funds

  126         126 

Total cash and cash equivalents

  14,184         14,184 
                 

Marketable investments:

                

U.S. government notes

  11,885      (15

)

  11,870 

Municipal securities

  201   
   (1

)

  200 

Commercial paper

  1,836      (3

)

  1,833 

Corporate debt securities

  7,838   2   (15

)

  7,825 

Total marketable investments

  21,760   2   (34

)

  21,728 
                 

Total cash, cash equivalents and marketable investments

 $35,944  $2  $(34

)

 $35,912 

 

 

As of June 30, 20172018 and December 31, 2016, total gross2017, net unrealized losses were $17,000$27,000 and $21,000,$34,000, respectively, and were related to interest rate changes on available-for-sale marketable and restricted investments. The Company has concluded that it is more-likely-than-not that the securities will be held until maturity or the recovery of their cost basis. No securities were in an unrealized loss position for more than 12 months.

 

The following table summarizes the contractual maturities of the Company’s available-for-sale securities, classified as marketable investments and restricted investments as of June 30, 20172018 (in thousands):

 

 

Amount

  Amount 

Due in less than one year

 $30,361  $9,573 

Due in 1 to 3 years

  4,174   1,000 

Total marketable investments

 $34,535  $10,573 

 

Note 3. 4. Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Carrying amounts of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate their fair values as of the balance sheet dates because of their generally short maturities. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable(observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs)(unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level(Level 1) and the lowest priority to unobservable inputs (Level(Level 3). The three levels of the fair value hierarchy are described below:below in accordance to ASC 820:

 

● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

● Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.

● Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.

Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

 

As of June 30, 2018, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):

June 30, 2018

 

Level 1

  

Level 2

  

Level 3

  

Total

 

Cash equivalents:

                

Money market funds

 $2,887  $  $  $2,887 
Marketable investments:                

Available-for-sale securities

     10,573      10,573 

Total assets at fair value

 $2,887  $10,573  $  $13,460 

As of December 31, 2017, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):

 

June 30, 2017

 

Level 1

  

Level 2

  

Level 3

  

Total

 

Cash equivalents:

                

Money market funds

 $982  $  $  $982 

Commercial paper

     6,093      6,093 

Marketable investments:

                

Available-for-sale securities

     32,270      32,270 

Restricted investments:

                

Money market funds

  25         25 

U.S. government notes

     2,265      2,265 

Total assets at fair value

 $1,007  $40,628  $  $41,635 

As of December 31, 2016, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above was as follows (in thousands):

December 31, 2016

 

Level 1

  

Level 2

  

Level 3

  

Total

 

December 31, 2017

 

Level 1

 
  

Level 2

  

Level 3

  

Total

 

Cash equivalents:

                                

Money market funds

 $6,053  $  $  $6,053  $126  $  $  $126 

Commercial paper

     1,050      1,050 

Marketable investments:

                

Available-for-sale securities

     40,299      40,299 

Marketable investments:

                

Available-for-sale securities

     21,728      21,728 

Total assets at fair value

 $6,053  $41,349  $  $47,402  $126  $21,728  $  $21,854 

 

 

The Company’sCompany’s Level 1 financial assets are money market funds with fair values that are based on quoted market prices. The Company’s Level 2 investments include U.S. government-backed securities and corporate securities that are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. The weighted average remaining maturity of the Company’s Level 2 investments as of June 30, 20172018 is less than 1 year7 months and all of these investments are rated by S&P and Moody’s at A-A or better. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the quarter and year ended June 30, 2018 and December 31, 2017, respectively.

 

Note 4. 5.BalanceSheetDetails

 

Inventories

 

As of June 30, 20172018 and December 31, 2016,2017, inventories consist of the following (in thousands):

 

 

June 30, 2017

  

December 31, 2016

  

June 30,

2018

  

 

December 31,

2017

 

Raw materials

 $12,248  $10,966  $17,875  $19,160 

Work in progress

  2,846   2,744 

Finished goods

  4,665   4,011   9,417   6,878 

Total

 $16,913  $14,977  $30,138  $28,782 

 

Accrued Liabilities

As of June 30, 20172018 and December 31, 2016,2017, accrued liabilities consist of the following (in thousands):

 

 

June 30, 2017

  

December 31, 2016

  

June 30,

2018

  

December 31,

2017

 

Accrued payroll and related expenses

 $9,006  $9,036  $10,712  $12,567 

Sales and marketing accruals

  2,283   3,710 

Warranty liability

  2,877   2,461   3,561   3,508 

Sales tax

  2,087   2,373   2,388   2,920 

Other

  5,003   3,527   3,812   4,143 

Total

 $18,973  $17,397  $22,756  $26,848 

 

Note 5.6. Warranty

The Company provides a standard one-year warranty on all systems. For direct sales to end customers, warranty coverage provided is for labor and parts necessary to repair the systems during the warranty period. For sales to distributors, we provide a 14 to 16 month warranty for parts only. The distributor provides the labor to their end customer.Service Contracts

 

The Company has a direct field service organization in the U.S. Internationally, the Company provides direct service support through its wholly-owned subsidiaries in Australia, Belgium, Canada, France,, Hong Kong, Japan, and Switzerland, as well as through third-party service providers in Spain and the United Kingdom. In several other countries, where itthe Company does not have a direct presence, the Company provides service through a network of distributors and third-party service providers.

 

After the original warranty period,period, maintenance and support are offered on a service contract basis or on a time and materials basis. The Company provides for the estimated cost to repair or replace products under warranty at the time of sale. The following table provides the changes in the product warranty accrual for the three and six months ended June 30, 20172018 and 20162017 (in thousands):

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

  

Six Months Ended

 
 

June 30,

  

June 30,

  

June 30,

  

June 30,

 
 

2017

  

2016

  

2017

  

2016

  

2018

  

2017

  

2018

  

2017

 

Beginning Balance

 $2,735  $1,819  $2,461  $1,819  $3,373  $2,735  $3,508  $2,461 

Add: Accruals for warranties issued during the period

  1,944   1,178   4,079   2,432   2,311   1,944   4,575   4,079 

Less: Settlements made during the period

  (1,802

)

  (997

)

  (3,663

)

  (2,251

)

  (2,123)   (1,802)

 

  (4,522)   (3,663)

 

Ending Balance

 $2,877  $2,000  $2,877  $2,000  $3,561  $2,877  $3,561  $2,877 

Note 7. Revenue

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time. Revenue from performance obligations that are transferred to customers over time accounted for approximately 9% of the Company’s total revenue for the six months ended June 30, 2018.

The Company's system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s system sale arrangements include a combination of the following performance obligations: the system and software license (considered as one performance obligation), system accessories (hand pieces), training, other accessories, extended service contracts and marketing services.

For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services (which are satisfied over time), the Company generally satisfies all of the performance obligations at a point in time. System, system accessories (hand pieces), training, time and material services are also sold on a stand-alone basis, and related performance obligations are satisfied at a point in time. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation, on a relative basis using its standalone selling price. The stated contract value is the transaction price to be allocated to the separate performance obligations.

Nature of Products and Services

Systems

System revenue represents the sale of a system or an upgrade of an existing system. A system consists of a console that incorporates a universal graphic user interface, a laser and or other energy based module, control system software and high voltage electronics, as well as one or more hand pieces. However, depending on the application, the laser or other energy based module is sometimes contained in the hand piece such as with the Company’s Pearl and Pearl Fractional applications instead of within the console.

The Company offers customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they choose and provides us with a source of additional Systems revenue.

The Company has concluded that the system or upgrade and the right to use the embedded software represent a single performance obligation as the software license is integral to the functionality of the system or upgrade.

The Company considers set-up or installation an immaterial promise as set-up or installation for systems other than enlighten systems takes only a short time. The related costs to complete set-up or installation are immaterial to the Company. The enlighten system is one performance obligation and the calibration or installation service is a separate performance obligation.

For systems sold directly to end-customers that are credit approved, revenue is recognized when the Company transfers control to the end-customer, which occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. The Company recognizes revenue on cash basis for system sales to international direct end-customer sales that have not been credit approved, after satisfying all remaining obligations of the agreement. For systems sold through credit approved distributors, revenue is recognized at the time of shipment. The Company’s system arrangements generally do not provide a right of return. The Company provides a standard one-year warranty coverage for all systems sold to end-customers to cover parts and service, and extended service plans that vary by the type of product and the level of service desired.

The Company typically receives payment for its system consoles and other accessories within 30 days of shipment. Certain international distributor arrangements allow for longer payment terms.

Skincare products

The Company sells third-party manufactured skincare products in Japan. The Company purchases and inventories these third-party skincare products from the manufacturers and sells them to licensed physicians. The Company acts as the principal in this arrangement, as it determines the price to charge customers for the skincare products, and controls the products before they are transferred to the customer. Skincare products are typically sold in contracts in which the skincare products represent the sole performance obligations. The Company recognizes revenue for skincare products at a point in time, generally upon shipment.

 

Note 6. Deferred Service Contract RevenueConsumables (Other accessories)

The Company treats its customers' purchase of replacement Titan, truSculpt 3D and truSculpt iD hand pieces as Consumable revenue, which provides the Company with a source of recurring revenue from existing customers. The Company’s recently launched Juliet and Secret RF products have single use disposable tips which need to be replaced after every treatment. Sale of these consumable tips further enhance the Company’s recurring revenue stream. Hand piece refills of the Company’s legacy truSculpt product are accounted for in accordance with the Company’s standard warranty and service contract policies.

 

Extended contract services

The Company offers post-warranty services to its customers through extended service contracts that cover preventive maintenance and or replacement parts and labor for a term of one, two, or three years, or by direct billing for detachable hand piece replacements, parts and labor. These post-warranty services serve as additional sources of recurring revenue from the Company’s installed product base. Service revenue is recognized over time as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. For the Company's performance obligations recognized over time, revenue is generally recognized using a time-based measure of progress reflecting generally consistent efforts to satisfy those performance obligations throughout the arrangement term.

Training

Sales of system to customers include training on the system to be provided within 90 days of purchase. The Company considers training as a separate performance obligation as customers can immediately benefit from the training due to the fact that the customer already has the system. Training is also sold separately from systems. The Company recognizes revenue for training when the training is provided. Training is not required for customers to use the systems.

Customer Marketing Support

In North America, the Company offers marketing and consulting phone support to its customers who purchase its truSculpt 3D and truSculpt iD systems. These customer marketing support services include a practice development model and marketing training, performed remotely with ongoing phone consultations for six months from date of purchase. The Company considers customer marketing support a separate performance obligation, and allocates and recognizes revenue over the six-month term of support. The Company determines the standalone selling price based on cost plus a margin.

Significant Judgments

More judgments and estimates are required under Topic 606 than were required under the previous revenue recognition guidance, Topic 605. Revenue recognition under Topic 606 for the Company’s arrangements may be dependent on contract-specific terms.

The enlighten system includes the related software license as one performance obligation and the calibration/installation services are accounted for as separate performance obligations. The calibration/installation is a separate performance obligation for the enlighten system because a knowledgeable third-party could perform this service.

The Company has however concluded that set-up or installation for all other systems (excluding the enlighten system) is perfunctory as the set-up or installation for systems other than enlighten take only a short time and the related costs to complete set-up or installation are immaterial.

Judgment is required to determine the standalone selling price ("SSP") for each distinct performance obligation. The Company estimates SSPs for each performance obligation as follows:

Systems: The SSPs for systems are based on directly observable sales in similar circumstances to similar customers.  When SSP is not directly observable, the Company estimates SSP using the expected cost plus margin approach.

Training: SSP is based on observable price when sold on a standalone basis.

Extended warranty: SSP is based on observable price when sold on a standalone basis (by customer type).

Marketing program: SSP is estimated based on cost plus margin.

The Company will combine two or more contracts entered into at or near the same time with the same customer (or related parties of the customer) and account for the contracts as a single contract. If a group of agreements are so closely related that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company’s judgments about whether a group of contracts comprise a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.

The Company is required to estimate the total consideration expected to be received from contracts with customers. In limited circumstances, the consideration expected to be received is variable based on the specific terms of the contract or based on the Company’s expectations of the term of the contract. Generally, the Company has not experienced significant returns or refunds to customers. These estimates require significant judgment and the change in these estimates could have an effect on its results of operations during the periods involved.

Deferred Sales Commissions

Incremental costs of obtaining a contract, including sales commissions, are capitalized and amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. The Company uses the portfolio method to recognize the amortization expense related to these capitalized costs related to initial contracts and such expense is recognized over a period associated with the revenue of the related portfolio, which is generally two to three years for the Company’s product and service arrangements.

Total capitalized costs as of June 30, 2018 were $5.3 million and are included in other long-term assets in the Company’s condensed consolidated balance sheet. Amortization of this asset was $0.4 million and $0.8 million, respectively, during the three and six months ended June 30, 2018 and is included in sales and marketing expense in the Company’s condensed consolidated statements of operations.

Note 8. Contract balance

The Company’s service contracts include an upfront payment for the one, two or three-year contract terms. The timing of receipt of payment and timing of performance of the services create timing differences that result in deferred revenue on the Company’s condensed consolidated balance sheet. The advance payments under these contracts are recorded in deferred revenue, and the Company recognizes the revenue when earned. Contracted but unsatisfied performance obligations were approximately $11.8 million as of June 30, 2018, of which the Company expects to recognize approximately 78% of the revenue over the next 12 months and the remainder thereafter.

The Company's deferred contract revenue consists of service revenue, training and product revenue. Deferred contract revenue balance is comprised mainly of Service revenue. The Company generates Service revenue from the sale of extended service contracts and from time and material services provided to customers who are not under a warranty or extended service contract. Service contract revenue is recognized on a straight-line basis over the period of the applicable contract. Service revenue from time and material services is recognized as the services are provided.

 

The following table provides changes in the deferred service contract revenue balance for the three and six monthmonths ended June 30, 20172018 and 20162017 (in thousands):

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

  

Six Months Ended

 
 

June 30,

  

June 30,

  

June 30,

  

June 30,

 
 

2017

  

2016

  

2017

  

2016

  

2018

  

2017

  

2018

  

2017

 

Beginning Balance

 $9,555  $10,512  $9,431  $10,469  $11,015  $9,555  $11,656  $9,431 

Add: Payments received

  3,721   3,045   7,112   6,308   4,739   3,721   8,416   7,112 

Less: Revenue recognized

  (3,263

)

  (3,334

)

  (6,530

)

  (6,554

)

  (3,947)   (3,263)

 

  (8,265)   (6,530)

 

Ending Balance

 $10,013  $10,223  $10,013  $10,223  $11,807  $10,013  $11,807  $10,013 

 

Costs for extended service contracts were $1.0 million and $1.6 million for the three months ended June 30, 2017 and 2016, respectively, and $2.9 million and $3.2 million for the six months ended June 30, 2017 and 2016, respectively.

Note 7. Stockholders’ Equity and Stock-based Compensation Expense

Amended and Restated 2004 Equity Incentive Plan

In the second quarter ended June 30, 2017, the Company’s board of directors (“Board”) and stockholders approved the amendment and restatement of the 2004 equity incentive plan (“Amended and Restated 2004 Equity Incentive Plan”). The amendments included the extension of the term of the plan to the date of the Annual Meeting of the Company’s stockholders in 2022, an increase in the number of shares available for future grant by 1,600,000 shares, and other terms of the plan. The Amended and Restated 2004 Equity Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, performance shares, and other stock or cash awards.

Share Repurchase Program

On February 8, 2016, the Company announced that its Board of Directors approved the expansion of its Stock Repurchase Program by $10 million, under which the Company is authorized to repurchase shares of its common stock. As of December 31, 2016, there remained an additional $5.1 million in the Stock Repurchase Program to use for repurchasing the Company’s common stock. On February 13, 2017 the Company’s Board of Directors approved the expansion of its Stock Repurchase Program by an additional $5 million.

In the three and six months ended June 30, 2017,2018, were $2.0 million and 3.9 million, respectively.

Note 9. Stockholders’ Equity and Stock-based Compensation Expense

In 1998, the Company repurchased 193,844 and 334,244adopted the 1998 Stock Plan, or 1998 Plan, under which 4,650,000 shares of itsthe Company’s common stock were reserved for approximately $4.1 millionissuance to employees, directors and $7.0 million, respectively. Asconsultants. On January 12, 2004, the Board of June 30, 2017, there remained an additional $3.1 million available inDirectors adopted the Stock Repurchase Program to repurchase2004 Equity Incentive Plan. A total of 1,750,000 shares of common stock. Allstock were originally reserved for issuance pursuant to the 2004 Equity Incentive Plan. In addition, the shares repurchased were retiredreserved for issuance under the 2004 Equity Incentive Plan included shares reserved but un-issued under the 1998 Plan and shares returned to authorized but unissued status.

On July 28, 2017 the Company's Board1998 Plan as the result of Directorstermination of options or the repurchase of shares. In 2012 the stockholders approved an incremental $25 milliona “fungible share” provision whereby each full-value award issued under the 2004 Equity Incentive Plan results in a requirement to be added tosubtract 2.12 shares from the Stock Repurchase Program.

Stock-based Compensation Expense

Stock-based compensation expense by department recognized duringshares reserved under the three months ended June 30, 2017 and 2016 were as follows (in thousands):Plan.

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2017

  

2016

  

2017

  

2016

 

Cost of revenue

 $147  $40  $276  $181 

Sales and marketing

  401   229   821   605 

Research and development

  239   105   476   285 

General and administrative

  444   376   1,053   1,011 

Total stock-based compensation expense

 $1,231  $750  $2,626  $2,082 

 

Activity under the Company’sCompany’s Amended and Restated 2004 Equity Incentive Plan, as amended, is summarized as follows:

 

     

Options Outstanding

      

Options Outstanding

 
 

Shares

Available

for Grant

  

Number of

Stock Options

Outstanding

  

Weighted-

Average Exercise

Price

  

Shares

Available

for Grant

  

Number of

Stock Options

Outstanding

  

Weighted-

Average Exercise

Price

 

Balance, December 31, 2016

  721,657   1,116,472  $9.56 

Additional shares reserved

  1,600,000       

Balance, December 31, 2017

  1,494,865   839,919  $16.46 

Options granted

  (85,500

)

  85,500   18.71   (21,010)   21,010   50.65 

Stock awards granted(1) (2)

  (486,614

)

      

Stock awards granted(1)

  (395,511)       

Options exercised

     (370,162

)

  8.88      (188,859)   9.98 

Options canceled

  31,393   (31,393

)

  14.38   43,833   (43,833)   20.33 

Stock awards canceled(1)

  97,823       

Balance, June 30, 2017

  1,878,759   800,417  $10.66 

Stock awards canceled(1)

  93,390       

Balance, June 30, 2018

  1,215,567   628,237  $19.28 

 

(1)

TheCompanyhasafungibleshare”provisioninitsAmendedandRestated2004EquityIncentivePlanwherebyforeachfull-valueaward(RSU/PSU)issuedorcanceledunderthePlan requires the subtraction or add back of 2.12 shares from or to the Shares Available for Grant, respectively.

(2)

Included in 'Stock awards granted' of 486,614, was 221,540the fungible shares relating to 104,500subtractionoraddback of PSUs granted. These PSUs may result in a lower number of shares of common stock that may be released on January2.12 1, 2018, based on PSUs forfeited due to employment terminations and the degree of achievement of twoshares performance goals compared to targets that were pre-determined by the Board and disclosed in a Form 8-K on Januaryfrom 11or, 2017.totheSharesAvailableforGrant,respectively.


 

Under the Amended and Restated 2004 Equity Incentive Plan,, as amended, the Company issued 241,696 shares and 426,903346,279 shares of common stock during the three and six months ended June 30, 2017, respectively,2018, in conjunction with stock options exercised and the vesting of RSUs and PSUs.

 

As of June 30, 2017,2018, there was approximately $4.9$19.8 million of unrecognized compensation expense, net of projected forfeitures, related to non-vested equityfor stock options and stock awards. The expense is expected to be recognized over the remaining weighted-average period of 1.812.5 years. The actual expense recorded in the future may be higher or lower based on a number of factors, including, actual forfeitures experienced and the degree of achievement of the performance goals related to the PSUs granted.

 

Non-Employee Stock-Based Compensation

The Company granted 3,384 RSUs and 3,384 PSUs to non-employees during the six months ended June 30, 2018, and 7,745 stock options and 2,478 RSUs during the year ended December 31, 2017. The stock options vest over 4 years at 25% on the first anniversary of the grant date and 1/48th each month thereafter. The RSUs vest over 4 years at 25% on each anniversary of the grant date, whiles vesting of the PSUs is subject to the recipient's continued service and achievement of pre-established metrics. These RSUs/PSUs and stock options were granted in exchange for consulting services to be rendered and are measured and recognized as they are earned. The Company revalues stock options granted to non-employees at each reporting date as the underlying equity instruments vest.

Stock-based Compensation Expense

Stock-based compensation expense by department recognized during the three and six months ended June 30, 2018 and 2017 were as follows (in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2018

  

2017

  

2018

  

2017

 

Cost of revenue

 $227  $147  $380  $276 

Sales and marketing

                

Employee

  660   401   1,112   821 

Non-Employee

  55      92    

Research and development

  262   239   453   476 

General and administrative

  1,002   444   1,856   1,053 

Total stock-based compensation expense

 $2,206  $1,231  $3,893  $2,626 

Note 8.10. Net Income (Loss)Loss Per Share

 

Basic net income (loss) per share is computed using the weighted-average number of shares outstanding during the period. In periods of net income, diluted shares outstanding include the dilutive effect of in-the-money equity awards (stock options, restricted stock units, performance stock units and employee stock purchase plan contributions), which is calculated based on the average share price for each fiscal period using the treasury stock method. UnderIn accordance with ASC 260, the assumed proceeds under the treasury stock method include the amountaverage unrecognized compensation expense of in-the money stock options and restricted stock units. This results in the employee must pay forassumed buyback of additional shares, thereby reducing the dilutive impact of equity award, and the amount of compensation cost for future service that the Company has not yet recognized, are all assumed to be used to repurchase shares. awards.

Diluted earnings per share is the same as basic earnings per share for the periods in which the Company had a net loss because the inclusion of outstanding common stock equivalents would be anti-dilutive.

 

The following table sets forth the computation of basic and diluted net lossincome (loss) and the weighted average number of shares used in computing basic and diluted net lossincome (loss) per share (in thousands, except per share data):

 

 

Three Months Ended

  

Six Months Ended

  Three Months Ended June 30,  Six Months Ended June 30, 
 

June 30,

  

June 30,

  2018  2017  2018  2017 
 

2017

  

2016

  

2017

  

2016

 

Numerator

                

Net income (loss) (in thousands)

 $1,947  $(1,229

)

 $925  $(3,280

)

Net income (loss)

 $(1,572)  $1,947  $(3,604)  $925 

Denominator

                                

Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic

  13,935   13,131   13,888   13,071 

Dilutive effect of incremental shares and share equivalents

  694      745    

Weighted average shares of common stock outstanding used in computing net

                

income (loss) per share, basic

  13,709   13,935   13,649   13,888 

Dilutive effect of incremental shares and share equivalents

     694      745 

Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted

  14,629   13,131   14,633   13,071   13,709   14,629   13,649   14,633 

Net income (loss) per share:

                                

Net income (loss) per share, basic

 $0.14  $(0.09

)

 $0.07  $(0.25

)

 $(0.11)  $0.14  $(0.26)  $0.07 

Net income (loss) per share, diluted

 $0.13  $(0.09

)

 $0.06  $(0.25

)

 $(0.11)  $0.13  $(0.26)  $0.06 

 

The following numbersnumbers of weighted shares outstanding, prior to the application of the treasury stock method, were excluded from the computation of diluted net income (loss) per common share for the period presented because including them would have had an anti-dilutive effect (in thousands):

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

  

Six Months Ended

 
 

June 30,

  

June 30,

  

June 30,

  

June 30,

 
 

2017

  

2016

  

2017

  

2016

  

2018

  

2017

  

2018

  

2017

 

Options to purchase common stock

  66   1,993   53   2,059   710   66   758   53 

Restricted stock units

  3   448   2   426   449   3   422   2 

Performance stock units

     151      144   49      36    

Employee stock purchase plan shares

     83      83   73      73    

Total

  69   2,675   55   2,712   1,281   69   1,289   55 

 

17

Note 9.11. Income Taxes

 

The Company calculates the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full fiscal year to ordinary”"ordinary" income or loss (pretax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. When applicable, the year-to-date tax provision reflects adjustments from discrete tax items. InThe income tax benefits for the quarter ended December 31, 2016, the Company adopted the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. As a result of the adoption of the ASU No. 2016-09, thethree and six months ended June 30, 2017 tax provision includes the discrete accounting of the net2018 reflect a projected income tax benefit of excess compensation cost (“windfalls”). In the periods priorfor U.S. and non-U.S. operations resulting in an annual effective tax rate applied to the adoption of ASU No. 2016-09, theyear-to-date ordinary loss. This tax benefit of windfallsis increased by excess tax benefits generated by stock deductions exercised or vested in the three and tax deficiencies (“shortfalls”) were recorded in equity to the extent of previous windfalls, and then to the income statement.six months ended June 30, 2018.

 

For the three and six month periodmonths ended June 30, 2016,2018, the Company used a discrete effectiveCompany's income tax rate methodbenefit was $712,000 and $3,331,000 respectively, compared to calculate the provision for income taxes. The Company determined that since small changes in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the fiscal six-month period ended June 30, 2016.

The Company’s income tax expense of $59,000 and income tax benefit of $59,000 for the same periods in 2017. The income tax benefits for the three and six months ended June 30, 2017, respectively, related primarily to the Company’s U.S. and non-U.S. operations based on the annual effective tax rate method. In addition, it included2018 include a tax benefit for excess tax deductions of approximately $59,000$1.14 million and $110,000$2.6 million, respectively, recorded discretely in the three and six months ended June 30, 2017, respectively. The Company’s income tax expense for the three and six months ended June 30, 2016 was $30,000 and $54,000, respectively, and related primarily to income taxes of the Company’s non-U.S. operations.reporting period.

 

The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using enacted tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As of June 30, 2017, and December 31, 2016,2017, the Company had a 100%released its valuation allowance against its U.S. federal and all other domestic state net deferred tax assets.assets except for California and Massachusetts. The Company maintained this valuation allowance position through June 30, 2018. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considered all available positive and negative evidence giving greater weight to its recent cumulative losses and lesser weight to its projected financial results due to the subjectivity involved in forecasting future periods.evidence. The Company also considered, commensurate with its objective verifiability, the forecast of future taxable income including the reversal of temporary differences, and the implementation of feasible and prudent tax planning strategies.strategies and the impact of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”).

Note 12. Correction of Prior Period Immaterial Error

During the three months ended June 30, 2018, management discovered that the Company had not recorded the tax effect of the adoption of ASC 606 in the balance sheet of the unaudited condensed consolidated financial statements as of March 31, 2018. Upon adoption of the Topic 606, the Company recorded an increase to retained earnings of $5.0 million for contracts still in force as of January 1, 2018. The tax effect of the 606 adoption was $1.2 million.

The Company evaluated the impact of the error on prior period and determined that the effect was not material to the financial statements as of and for the three months ended March 31, 2018 and six months ended June 30, 2018. The Company corrected the error in the unaudited condensed consolidated financial statements as of and for the six months ended June 30, 2018. The correction of the error increased deferred tax liability by $1.2 million and decreased retained earnings by $1.2 million (Note 2) as of January 1, 2018.

The Company’s condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2018, and the three and six months ended June 30, 2018 were not affected by this correction of the error. Accordingly, the Company's loss per share for the three months ended March 31, 2018, and the three and six months ended June 30, 2018 remains unchanged.

Note 13. Segment reporting

Segment reporting is based on the “management approach,” following the method that management organizes the company’s reportable segments for which separate financial information is made available to, and evaluated regularly by, the chief operating decision maker in allocating resources and in assessing performance. The Company’s chief operating decision maker ("CODM") is its Chief Executive Officer ("CEO"), who makes decision on allocating resources and in assessing performance. The CEO reviews the Company's consolidated results as one operating segment. In making operating decisions, the CEO primarily considers consolidated financial information, accompanied by disaggregated information about revenues by geography and product. All of the Company’s principal operations and decision-making functions are located in the U.S. The Company’s CEO viewed its operations, managed its business, and used one measurement of profitability for the one operating segment — which sells aesthetic medical equipment and services, and distributes skincare products, to qualified medical practitioners. Substantially all of the Company’s long-lived assets are located in the U.S.

The following table presents a summary of revenue by geography for the three months ended June 30, 2018 and 2017 (in thousands):

 

  

Three Months Ended June 30,

 
  

2018

  

2017

 

Revenue mix by geography:

        

United States

 $28,132  $24,239 

Japan

  3,946   3,710 

Asia, excluding Japan

  4,231   2,830 

Europe

  1,803   1,219 

Rest of the world

  4,441   4,391 

Total consolidated revenue

 $42,553  $36,389 

Revenue mix by product category:

        

Products

 $35,291  $30,115 

Consumables

  1,057   649 

Skincare

  1,302   963 

Total product revenue

 $37,650  $31,727 

Service

  4,903   4,662 

Total consolidated revenue

 $42,553  $36,389 

The following table presents a summary of revenue by geography for the six months ended June 30, 2018 and 2017 (in thousands):


  

Six Months Ended June 30,

 
  

2018

  

2017

 

Revenue mix by geography:

        

United States

 $49,268  $40,783 

Japan

  7,501   7,590 

Asia, excluding Japan

  7,074   6,014 

Europe

  4,373   3,445 

Rest of the World

  8,462   7,856 

Total consolidated revenue

 $76,678  $65,688 

Revenue mix by product category:

        

Products

 $62,530  $53,107 

Consumables

  1,826   1,148 

Skincare

  2,558   1,947 

Total product revenue

 $66,914  $56,202 

Service

  9,764   9,486 

Total consolidated revenue

 $76,678  $65,688 

18

Note 1014. Commitments and Contingencies

 

TheOperating Leases

The Company leases space for operations in the United States, Spain, Japan and France. Future minimum lease commitments under the Company’s facility operating leases were as follows (in thousands):

Year Ending December 31

 

Amount

 

2018

 $1,494 

2019

  2,971 

2020

  2,913 

2021

  2,525 

2022

  2,495 

2023 and beyond

  214 

Total future minimum lease payments

 $12,612 

In addition to the above facility leases, the Company also routinely leases automobiles for certain sales and field service employees under capital leases. The remaining committed lease payments as of June 30, 2018 was $1.15 million.

Contingencies

The Company is named from time to time as a party to other legal proceeds product liability, commercial disputes, employee disputes, and contractual lawsuits and other general corporate matters in the normal course of business. The Company routinely assessesA liability and related charge are recorded to earnings in the likelihood of any adverse judgments or outcomes related toCompany’s consolidated financial statements for legal matters and claims, as well as ranges of probable losses. A determination of the amount of the reserves required, if any, for these contingencies is made after analysis of each known issue, historical experience, whether it is more likely than not that the Company shall incur a loss, and whetherwhen the loss is estimable.

considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible, but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. The Company is not currently a party to any materialexpenses legal proceedings.

Note 11. Subsequent Events

On May 2, 2017, the Company entered into a new building lease with the intent to relocate its corporate headquarters to a new facility in Fremont, California. On July 6, 2017, the Company terminated this lease in return for a lump sum receipt from the lessor of $4.0 million. In conjunction with this lease termination, the Company cancelled a standby letter of credit that it had provided to the landlordfees as a security deposit, which removed all restrictions on $2.3 million of investments that were used to secure the standby letter of credit and recorded as “Restricted investments” in the balance sheet as of June 30, 2017. Simultaneously with the execution of the lease termination, the Company entered into an amendment to its existing lease agreement for the Company to maintain its corporate headquarters in its current facility in Brisbane, California. This amendment extends the term of the lease from December 31, 2017 to January 31, 2023.incurred.

 

As of June 30, 2018 and December 31, 2017, the Company had $3.1 million remaining under its Stock Repurchase Program. On July 28, 2017, theaccrued $137,000 and $91,000, respectively related to various pending contractual and product liability lawsuits. The Company’s Board does not believe that a material loss in excess of Directors approved an additional $25 million to be added to the program.accrued amounts is reasonably possible.

 


19

 

Note 15. Debt

Loan and Security Agreement

On May 30, 2018, the Company and Wells Fargo Bank, N.A. (“Wells Fargo”) entered into a Loan and Security Agreement (the “Revolving Line of Credit”) in the original principal amount of $25,000,000. The Revolving Line of Credit terminates on May 30, 2021. The purpose of the Revolving Line of Credit is to provide working capital and to fund the Company’s general business requirements.

The Revolving Line of Credit bears interest at a variable interest rate equal to the LIBOR Rate plus a defined LIBOR Rate Margin based on the then-current Leverage Ratio (a ratio of funded debt to the Trailing Twelve Month ("TTM") Adjusted EBITDA).

The Revolving Line of Credit provides for borrowing limits that range from $5,000,000 to a maximum of $25,000,000 during the term of the Revolving Line of Credit. Additionally, the Company agrees to pay a variable unused commitment fee to Wells Fargo equal to (a) 0.25% per annum if the Leverage Ratio is less than 1.0 to 1.0, (b) 0.30% per annum if the Leverage Ratio is equal to or greater than 1.0 to 1.0, but less than 2.0 to 1.0, and (c) 0.35% per annum if the Leverage Ratio is equal to or greater than 2.0 to 1.0.

The Revolving Line of Credit is secured by a pledge of security interest in all the shares of each material subsidiary, together with all proceeds, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted, and all other cash and noncash proceeds, as security for the performance of the obligations. As of June 30, 2018, there were no borrowings under the Revolving Line of Credit.

Covenants 

The Loan and Security Agreement contains financial and other covenants as well as the maintenance of a leverage ratio not to exceed 2.5 to 1.0 and a TTM adjusted EBITDA of not less than $10 million. A violation of any of the covenants could result in a default under the Loan and Security Agreement that would permit the lenders to restrict the Company’s ability to further access the revolving line of credit for loans and letters of credit and require the immediate repayment of any outstanding loans under the Loan and Security Agreement. As of June 30, 2018, the Company is in compliance with all financial covenants.

20

ITEM 2.

ITEM 2.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Caution Regarding Forward-Looking Statements

 

ThisYou should read the following management’s discussion and analysis of the Company’s financial condition and results of operations in conjunction with the Company’s unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q (“and with the audited financial statements and notes thereto for the year ended December 31, 2017, included in the annual report on Form 10-Q”)10-K filed on March 26, 2018 with the U.S. Securities and Exchange Commission (SEC).

Special note regarding forward-looking statements

This report contains forward-looking statements that involve risks and uncertainties. The Company’s actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”("the Exchange Act"). The Private Securities Litigation Reform ActForward-looking statements are often identified by the use of 1995 provides a “safe harbor” for certain forward-looking statements. The words such as, but not limited to, “anticipate,” “believe,” “potential,“can,“forecast,“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “expect,” “anticipate,” “plan,” “intend,” “foresee,“seek,” “should,” “would,“strategy,“could,“target,“may,“will,“estimate,” “project” or other“would” and similar expressions areor variations intended to identify forward-lookingforward- looking statements. These forward-looking statements are based on our current expectationsthe beliefs and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we anticipate. All comments concerning our expectations for future revenues and operating results areassumptions of the Company’s management based on our forecasts for our existing operations. Theseinformation currently available to management. Such forward-looking statements involve significantare subject to risks, uncertainties and uncertainties (someother important factors that could cause actual results and the timing of whichcertain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are beyond our control)not limited to, those identified below and assumptions. Theythose discussed in the section titled “Risk Factors” included under Part II, Item 1A below.

Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. The statements are subject to change based on various factors, including but not limited to the risks and uncertainties summarized below:

 

changes in ourthe Company’s common stock price;

changes in our profitability;
regulatory activities and announcements, including

the inability for the Company to access cash due to insufficient cash or the failure to meet the debt repayment obligations under the Revolving line of credit;

the ability of the Company’s sales force to effectively market and promote the Company’s products, and the extent to which those products gain market acceptance;

the possibility that cybersecurity breaches and other disruptions could compromise our information or result in the unauthorized disclosure of confidential information;

the existence and timing of any product approvals or changes;

the rate and size of expenditures incurred on the Company’s clinical, manufacturing, sales, marketing and product development efforts;

the Company’s ability to obtain and retain personnel;

the availability of key components, materials and contract services, which depends on the Company’s ability to forecast sales, among other things;

investigations of the Company’s business and business-related activities by regulatory or other governmental authorities;

variations in timing and quantity of product orders;

temporary manufacturing interruptions or disruptions;

the timing and success of new product and new market introductions, as well as delays in obtaining domestic or foreign regulatory approvals for oursuch introductions;

increased competition, patent expirations or new products;technologies or treatments;

product recalls or safety alerts;

effectiveness of our internal controls over financial reporting;

litigation, including product liability, patent, employment, securities class action, stockholder derivative, general commercial and other lawsuits;

fluctuations in future quarterly operating results;
failure to comply with, or changes in, laws, regulations or administrative practices
affecting government regulation of our products, including, but not limited to, United States (“U.S.”) Food and Drug Administration (“FDA”) laws and regulations;
failure to establish, expand or maintain market acceptance or payment for the purchase of our products;
failure to maintain the current regulatory approvals for our indications;
unfavorable results from clinical studies;
variations in sales and operating expenses relative to estimates;
our dependence on certain suppliers and manufacturers to provide certain materials, components and contract services necessary for the production of our products;
product liability-related losses and costs;
protection, expiration and validity of our intellectual property;
changes in technology, including the development of superior or alternative technology or devices by competitors;
failure to comply with applicable domestic laws and regulations, including federal and state privacy and security laws and regulations;
failure to comply with foreign law and regulations;
international operational and economic risks and concerns;
failure to attract or retain key personnel;
losses or costs from pending or future lawsuits and governmental investigations;
changes in accounting rules that adversely affect the characterization of our consolidated results of income, financial position or cash flows;
changes in customer spending patterns;

continued volatility in the global market and worldwide economic conditions;conditions, including, but not limited to, the impact of events such as Brexit;

changes in tax laws, including the new U.S. tax reform, and changes due to Brexit, or exposure to additional income tax liabilities;

the impact of the new European Union privacy regulations (the General Data Protection Regulation) on the Company’s resources - the failure to comply could result in fines;

the financial health of the Company’s customers and their ability to purchase the Company’s products in the current economic environment; and;

weather

other unusual or natural disasters that interrupt our business operationsnon-operating expenses, such as expenses related to mergers or the business operations of our customers.acquisitions, may cause operating result variations.

 

Other factors that could cause our actual results to differ from our projected results are described in (1) “Part II, Item 1A. Risk Factors” and elsewhere in this Form 10-Q, (2) our Annual Report on Form 10-K for the period ended December 31, 2016 (“2016 Form 10-K”), (3) our reports and registration statements filed and furnished from time to time with the U.S. Securities and Exchange Commission (“SEC”) and (4) other announcements we make from time to time.Introduction

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof.  We undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise. You should read the following discussion and analysis in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this report. Operating results for the twenty-six weeks ended June 30, 2017 are not necessarily indicative of future results, including the full fiscal year. You should also refer to our “Annual Consolidated Financial Statements,” “Notes” thereto, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” contained in our 2016 Form 10-K.

Introduction

The Management’sManagement’s Discussion and Analysis, or MD&A, is organized as follows:

 

ExecutiveSummary.This section provides a general description and history of ourthe Company’s business, a brief discussion of ourthe Company’s product lines and the opportunities, trends, challenges and risks we focus on in the operation of ourthe Company’s business.

Critical Accounting Policies and Estimates.AccountingPoliciesandEstimates.This section describes the key accounting policies that are affected by critical accounting estimates.

ResultsofOperations.This section provides ourthe Company’s analysis and outlook for the significant line items on ourthe Company’s Condensed Consolidated Statements of Operations.

LiquidityandCapitalResources.This section provides an analysis of ourthe Company’s liquidity and cash flows, as well as a discussion of our commitments.the Company’s commitments that existed as of June 30, 2018.

21

Table of Contents

 

Executive Summary

 

Company Description.Description

 

We are a leading medical device company specializing in the research, development, manufacture, marketing and servicing of laser and other energy-basedenergy based aesthetics systems for practitioners worldwide. In addition to internal development of products, we distribute third party sourced products under the Company’s own brand names. We offer easy-to-use products which enable physicians and other qualified practitioners to perform safe and effective aesthetic procedures, including treatment of vascular conditionsfor body contouring, skin resurfacing and rejuvenation, tattoo removal, removal of benign pigmented lesions, vascular conditions, hair removal, skin rejuvenation, body contouring, skin resurfacing, tattoo removal and toenail fungus treatment. Ourand vaginal health. The Company’s platforms are designed to be easily upgraded to add additional applications and hand pieces, which provide flexibility for ourthe Company’s customers as they expand their practices. The sales of systems, system upgrades, hand pieces, hand piece refills (applicable to Titan and truSculpt) and the distribution of third party manufactured skincare products are classified as “Products” revenue. In addition to Productssystems and upgrade revenue, we generate revenue from the sale of post-warrantypost warranty service contracts, parts, detachable hand piece replacements (exceptproviding services forTitan and truSculpt) and service labor for the repair and maintenance of products that are out of warranty, allhand piece refills, and distribution of which is classified as “Service” revenue.third-party manufactured skincare products.

 

OurThe Company’s ongoing research and development activities are primarily focused on improving and enhancing the Company’s portfolio of products. The Company is exploring ways to expand the Company’s product offerings through the launch of new products. The Company introduced Juliet, a product for women’s health, in December 2017, SecretRF, a fractional RF microneedling device for skin rejuvenation, in January 2018, enlighten SR in April 2018, and truSculpt iD in July 2018.

The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, from where we conduct ourthe Company conducts manufacturing, warehousing, research and development,development, regulatory, sales and marketing, service, and administrative activities. We have wholly-owned subsidiariesThe Company markets, sells and services the Company’s products through direct sales and service employees in the U.S., Australia, Belgium, Canada, France, Hong Kong, Japan, Spain, Switzerland and the United Kingdom. We market, sellSales and service our productsService outside of the United Statesthese direct markets are made through our direct employees, third party service providers, as well as a globalworldwide distributor network in over 40 countries.


 

Products and Services

OurThe Company’s revenue is derived from the sale of Products and Services. Our ProductsProduct revenue is derived from the sale of Systems, Hand piece refills (applicablesystems, hand pieces and upgrade of systems (“Systems” revenue), sale of replacement hand pieces, as well as single use disposable tips applicable to TitanJuliet, Secret RF and truSculpt)(“Consumables” revenue), and the distributionsale of third party manufactured Skincare products. Systems revenue includes the sales of new systems and additional applications that customers purchase as their practice grows.skincare products (“Skincare” revenue). A system consists of a console that incorporates a universal graphic user interface, a laser and/or other energy-basedenergy based module, control system software and high voltage electronics, andas well as one or more hand pieces. OurHowever, depending on the application, the laser or other energy based module is sometimes contained in the hand piece such as with the Company’s Pearl and Pearl Fractional applications instead of within the console.

The Company offers customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they choose and provides us with a source of additional Systems revenue.

Skincare revenue relates to the distribution of ZO’s skincare products in Japan.

The Company’s primary system platforms include:

enlighten

excel HR

truSculpt

excel V

xeo

Other than the above mentioned five primary systems, we continue to generate revenue from our legacy products such as GenesisPlusTM, CoolGlide®, and a third-party sourced system called myQ® for the Japanese market. We have renewed our distribution contract for the sale of myQ in Japan on a non-exclusive basis through September 30, 2018. For our Titan and excel V, excel HR, enlighten, Juliet, Secret RF, truSculpt hand pieces, after a set number of treatments have been performed, the customer is required to send the hand piece back to the factory for refurbishment, which we refer to as “andrefilling xeo” the hand piece. In Japan, we distribute ZO Medical Health Inc. (“ZO”) skincare products.

 

ServiceService revenue relates to amortization of prepaid service contracts, training, enlighten installation, direct billings for detachable hand piece replacements (except for Titanand truSculpt) and revenue for parts and labor on out-of-warranty products.

 

Significant Business Trends

We believeThe Company believes that our the ability to grow revenue will be primarily dependent on the following:

 

Consumer demand for the applications of our products.

Customer (physicians and other practitioners) demand for our products.

Continuingcontinuing to expand ourthe Company’s product offerings, both through internal development and sourcing from other vendors.vendors;

Ongoingongoing investment in ourthe Company’s global sales and marketing infrastructure.infrastructure;

Useuse of clinical results to support new aesthetic products and applications.applications;

Increaed collaboration with key opinion leaders of our industry to assist us in selling efforts.

Marketingenhanced luminary development and reference selling efforts (to develop a location where Company’s products can be displayed and used to assist in selling efforts);

customer demand for the Company’s products;

strengthening against the U.S. dollar of key international currencies in which we transact (e.g. Australian Dollar, Japanese Yen, Euro, Swiss Franc and British Pound);

consumer demand for the application of the Company’s products;

marketing to physicians in the core dermatology and plastic surgerysurgeon specialties, as well as outside those specialties.specialties; and

Generating ongoinggenerating recurring revenue from our growingthe Company’s growing installed base of customers through the sale of systems, system upgrades, services, hand piece refills, skincare products and services.replacement tips for Julietand SecretRFproducts.

 

For a detailed discussion of the significant business trends impacting ourthe Company’s business, please see the section titled “Results of Operations” below.

 

Factors that May Impact Future Performance.Performance

OurThe Company’s industry is impacted by numerous competitive, regulatory macroeconomic and other significant factors. OurThe Company’s industry is highly competitive and ourthe Company’s future performance depends on ourthe Company’s ability to compete successfully. Additionally, ourthe Company’s future performance depends on ouris dependent upon the ability to continue to expand ourthe Company’s product offerings developwith innovative technologies, obtain regulatory clearances for ourthe Company’s products, protect the proprietary technology of ourthe products and our manufacturing processes, manufacture ourthe products cost-effectively, and successfully market and distribute ourthe products in a profitable manner. If we failthe Company fails to execute on the aforementioned initiatives, ourthe Company’s business couldwould be adversely affected. A detailed discussion of these and other factors that could impact ourthe Company’s future performance are provided in

(1) “Part II,Part I, Item 1A. Risk1A “Risk Factors” and elsewhere in this Form 10-Q, (2) our 2016the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, (3) ourthe Company’s reports and registration statements filed and furnished from time to time with the SEC, and (4) other announcements we makethe Company makes from time to time.

22

Critical Accounting Policiesaccounting policies, significant judgments and Estimates.use of estimates

The Company's management discussion and analysis of financial condition and results of operations are based upon the Company’s unaudited condensed consolidated financial statements. For the three and six months ended June 30, 2018, the Company’s income tax benefit was $712,000 and $3,331,000, respectively, compared to income tax expense of $59,000 and income tax benefit of $59,000 for the same periods in 2017. In the six months ended June 30, 2018, the Company calculated the provision for income taxes for interim reporting periods by applying an estimate of the "annual effective tax rate" for the full year to ordinary income or loss for the reporting period. The Company’s income tax benefit for the six months ended June 30, 2018 reflects a projected income tax benefit for U.S. and non-U.S. operations resulting in an annual effective tax rate applied to the year-to-date ordinary loss. The income tax benefit includes excess tax benefits generated by stock deductions exercised or vested in the six months ended June 30, 2018.

For the Company’s income tax provision in the six months ended June 30, 2017, the tax benefit was primarily related to projected U.S. alternative minimum taxes and income taxes from non-U.S. operations. The income tax benefit resulted from applying the annual effective tax rate by the year-to-date ordinary loss. The projected income tax reflected utilization of net operating loss carryforwards. However, the tax effect of such utilization was offset by a change in valuation allowance for the six months ended June 30, 2017 condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, (“U.S. GAAP”). The preparation of our Condensed Consolidated Financial Statements and related disclosures in conformity with GAAPthese condensed consolidated financial statements requires us to make estimates judgments and assumptionsjudgments that affect the reported amounts of assets, liabilities revenue and expenses. TheseOn an ongoing basis, we evaluate the Company’s critical accounting policies and estimates. The Company based the estimates judgments and assumptions are based on historical experience and on various other factorsassumptions that we believethe Company believes to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are reasonable under the circumstances. We periodically review our estimates and make adjustments when facts and circumstances dictate. To the extent that there are material differences betweennot readily apparent from other sources. Actual results may differ from these estimates under different assumptions and actual results, ourconditions. The Company’s significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial condition or results of operations will be affected.


Critical accounting estimates, as defined by the SEC, are those that are most importantstatements and in Note 2 to the portrayalCompany’s audited consolidated financial statements contained in the Annual Report on Form 10-K filed on March 26, 2018 with the SEC. With the exception of our financial conditionthe change in revenue recognition as a result of the adoption of ASC Topic 606, (see Notes 2 and results of operations and require our management’s most difficult and subjective judgments and estimates of matters that are inherently uncertain. The7) there have been no new or material changes to the critical accounting policies and estimates discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, that we consider to be critical, subjective, and requiring judgment in their application are summarized in “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2016 Form 10-K. There have been no significant changessignificance, or potential significance to the accounting policies and estimates disclosed in our Form 10-K.Company.

 

Results of Operations

 

The following table sets forth selected consolidated financial data for the periods indicated, expressed as a percentage of total revenue,revenue, net. Percentages in this table and throughout ourthe Company’s discussion and analysis of financial condition and results of operations may reflect rounding adjustments.

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

  

Six Months Ended

 
 

June 30,

  

June 30,

  

June 30,

  

June 30,

 
 

2017

  

2016

  

2017

  

2016

  

2018

  

2017

  

2018

  

2017

 
                                

Net revenue

  100

%

  100

%

  100

%

  100

%

  100%   100%

 

  100%   100%

 

Cost of revenue

  42

%

  42

%

  44

%

  43

%

  47%   42%

 

  48%   44%

 

Gross margin

  58

%

  58

%

  56

%

  57

%

  53%   58%

 

  52%   56%

 

                                

Operating expenses:

                                

Sales and marketing

  35

%

  39

%

  36

%

  39

%

  37%   35%

 

  37%   36%

 

Research and development

  8

%

  10

%

  9

%

  11

%

  10%   8%

 

  10%   9%

 

General and administrative

  10

%

  14

%

  10

%

  14

%

  12%   10%

 

  13%   10%

 

Total operating expenses

  53

%

  63

%

  55

%

  64

%

  59%   53%

 

  60%   55%

 

                                

Income (loss) from operations

  5

%

  (5

)%

  1

%

  (7

)%

  (5)%   5%

 

  (9)   1%

 

Interest and other income, net

  1

%

  1

%

  1

%

  1

%

Interest and other income (expense), net

     1%

 

     1%

 

Income (loss) before income taxes

  6

%

  (4

)%

  2

%

  (6

)%

  (5)%   6%

 

  (9)   2%

 

                                

Provision for income taxes

  

%

  

%

  

%

  

%

Provision (benefit) for income taxes

        (4)%    

Net income (loss)

  6

%

  (4

)%

  2

%

  (6

)%

  (5)%   6%

 

  (5)%   2%

 

23

Revenue

The Company primarily generates revenue from the sale of systems, training on the systems, extended service contracts, consumables and other accessories. The timing of the Company’s revenue is significantly affected by the mix of system products, installation, training, consumables and extended contract services. The revenue generated in any given period is also impacted by whether the revenue is recognized over time or at a point in time, upon completion of delivery. For an additional description on revenue, see Note 2 in the notes to consolidated financial statements on the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and Notes 2 and 7 in the accompanying unaudited condensed consolidated financial statements.

As of June 30, 2018, approximately 9% of the Company’s revenue is recognized over time, and the remainder of the revenue is recognized upon completion of delivery. Revenue recognized over time relates to revenue from the Company’s extended service contracts and customer marketing support. Revenue recognized upon delivery is primarily generated by the sales of system, consumables and skincare.

During the first and second quarters of fiscal year 2018, the Company recognized revenue based on the ASU No.2014-09, “Revenue from Contracts with Customers (Topic 606),” but revenue for the three and six months ended June 30, 2017 was recognized based on Topic 605. Therefore, the periods are not directly comparable. For additional information on the impact of the new accounting standard on the Company’s revenue, see Notes 2 and 7 in the accompanying unaudited condensed consolidated financial statements.

 

Total Net Revenue

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Revenue mix by geography:

                                                

United States

 $24,239   53% $15,806  $40,783   52% $26,860  $28,132   16%  $24,239  $49,268   21%

 

 $40,783 

International

  12,150   4%  11,671   24,905   8%  23,040   14,421   19%   12,150   27,410   10%

 

  24,905 

Consolidated total revenue

 $36,389   32% $27,477  $65,688   32% $49,900  $42,553   17%  $36,389  $76,678   17%

 

 $65,688 
                                                

United States as a percentage of total revenue

  67%      58%  62%      54%  66%

 

      67%

 

  64%

 

      62%

 

International as a percentage of total revenue

  33%      42%  38%      46%  34%

 

      33%

 

  36%

 

      38%

 

                                                

Revenue mix by product category:

                                                

Systems – North America

 $22,626   63% $13,888  $37,086   62% $22,912 

Systems – International

  7,489   7%  6,976   16,021   11%  14,465 
Systems                        

- North America

 $25,886   14%  $22,626  $44,830   21%

 

 $37,086 

- Rest of World

  9,405   26%   7,489   17,700   10%

 

  16,021 

Total Systems

  30,115   44%  20,864   53,107   42%  37,377   35,291   17%   30,115   62,530   18%

 

  53,107 

Hand Piece Refills

  649   (10

%)

  720   1,148   (11

%)

  1,284 

Consumables

  1,057   63%   649   1,826   59%

 

  1,148 

Skincare

  963   11%  870   1,947   11%  1,749   1,302   35%   963   2,558   31%

 

  1,947 

Total Products

  37,650   19%   31,727   66,914   19%

 

  56,202 
                  
                  

Service

  4,662   (7

%)

  5,023   9,486   %  9,490   4,903   5%   4,662   9,764   3%   9,486 

Consolidated total revenue

 $36,389   32% $27,477  $65,688   32% $49,900 

Total Net Revenue

 $42,553   17%  $36,389  $76,678   17%

 

 $65,688 


 

Total Net RevenueRevenue:

:

OurThe Company’s revenue increased by 32% in both17% for the three month and six monthmonths periods ended June 30, 2017,2018, compared to the same periods in 2016,2017, due primarily to increased system revenues.

an increase in the volume of systems sold.

Revenue by Geography:

Our

The Company’s U.S. revenue increased by $8.4$3.9 million, or 53%16%, and by $13.9$8.5 million, or 52%, in21% respectively for the three and six months ended June 30, 2017, respectively,2018, compared to the same periods in 2016.2017. This growthincrease was due primarily to an increasenew products introduced into the market in the volume of systems sold, as the result of the launch of our second generation truSculpt 3D product in the second quarter ended June 30, 2017, as well as increased sales headcount and additional marketing and promotional activities.January 2018.

Our

The Company’s international revenue increased by $479,000,$2.3 million, or 4%19%, and by $1.9$2.5 million, or 8%, in10% for the three and six months ended June 30, 2017,2018, compared to the same periods in 2016. These increases were2017. The increase was due primarily to growth in our directthe Company’s business in Hong Kong and Japan as well as an increase in distributor business inEurope, the Middle East partially offset by declines in revenue from our direct countries in Europe, and our Asia and Latin America distributors.including Japan.

Revenue by Product Type:

SystemsRevenue

Systems revenue in North America increased by $8.7$3.3 million, or 63%14%, and by $14.2$7.7 million, or 62%21% , inrespectively, for the three and six months ended June 30, 2017, respectively,2018, compared to the same periods in 2016. This growth was2017, due primarily to anstrong sales in the U.S. and new products launched since the second quarter of 2017. The Rest of the World systems revenue increased by $2.0 million or 26%, and $1.7 million, or 10%, respectively. The increase in volumeRest of truSculpt 3D the World revenue was primarily a result of increase in the Company’s direct business in Asia, including Japan, as well as increases in the Company’s distributor business in the Middle East and other platforms, which was drivenEurope, partially offset by decreases in part by additional sales headcount, higher productivity of our sales representatives,the Company’s direct business in Australia and the positive impact of additional marketing and promotional activities.Europe.

Systems

ConsumablesRevenue

Consumables revenue outside of North America (“International”) increased by $513,000,$408,000, or 7%63%, and by $1.6 million,$678,000, or 11%, in59% for the three and six months ended June 30, 2017,2018, respectively, compared to the same periods in 2016. This growth2017. The increase in consumables revenue was attributable primarilydue to increasedthe introduction of truSculpt 3D in May 2017, Secret RF and Juliet during January 2018, each of which have consumable elements.

24

SkincareRevenue

The Company’s revenue from xeo and excel HR,partially offsetSkincare products in Japan increased by declines in the volume of our first generation truSculpt product (truSculpt 3D has not yet been launched internationally).

Hand Piece Refills Revenue

Our Hand Piece Refills revenue decreased by $71,000,$339,000, or 10%35%, and by $136,000,$611,000, or 11%, in31% for the three and six months ended June 30, 2017,2018, respectively, compared to the same periods in 2016. These decreases were caused2017. This increase was due primarily by reduced utilization of the to increased marketing and promotional activities.

TitanService hand pieces.Revenue

 

Skincare Revenue

OurThe Company’s Service revenue from Skincare products in Japan increased by $93,000,$241,000, or 11%5%, and by $198,000,$278,000, or 11%, in3% for the three and six months ended June 30, 2017,2018, respectively, compared to the same periods in 2016. These increases were2017. This increase was due primarily to increased marketing and promotional activities for this distributed product.

Service Revenue

Our worldwide Service revenue decreased by $361,000, or 7%, in the three months ended June 30, 2017, compared to the same period in 2017. This decrease was due primarily to decreased sales of system parts to ourthe Company's network of international distributors. Our worldwide Service revenue was flat in the six months ended June 30, 2017, when compared to the same period in 2016.

 

Gross Profit

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Gross profit

 $21,046   31

%

 $16,005  $36,567   28

%

 $28,479  $22,377   6%

 

 $21,046  $39,711   9%

 

 $36,567 

As a percentage of total net revenue

  58

%

      58

%

  56

%

      57

%

  53%

 

      58%

 

  52%

 

      56%

 

 

OurThe Company’s cost of revenue consists primarily of material, personnel expenses, product warranty costs, amortization of intangibles and manufacturing overhead expenses.


 

Gross marginmargins in the three months ended June 30, 2017, compared to same period in 2016, remained flat at 58%. This was due primarily to:

An improvement in margins resulting from an $8.9 million increase in total net revenue, which improved the leverage of our manufacturing department expenses;
An increase in the volume of truSculpt 3D system sales that have a higher margin than our enlightenandexcel HR products; offset by
Increased service and warranty related expenses for some of our system platforms that are more complex and have a higher material cost, compared to our legacy systems.

Gross margin in the six months ended June 30, 20172018 decreased to 56%,by 5% and 4% respectively, compared to 57% in the same period in 2016. This decrease was2017.  In each of the three and six month periods, a higher percentage of product revenue came from our distributor network in Rest of the World. Reduced gross margins were due primarily to:

 

    In the three months ended June 30, 2018, Rest of World product revenue generated from distributors increased to 65% from 50% for the same period in 2017;

● In the six months ended June 30, 2018, Rest of World product revenue generated from distributors increased to 60% from 49% for the same period in 2017;
Margin improvements resulting fromSlightly lower average system pricing across the increased numberlegacy portfolio. The Company experienced continued pricing pressure on the average selling price of systems sold that improved the leverage of our manufacturing department expenses;Company’s enlighten system due to ongoing sales programs and normal business activities; and

Improved margins from truSculpt 3D system sales that have a higher margin than our enlighten and excel HR products; offset by
Reduced margins resulting from a higher percentage of total revenue coming from our enlighten and excel HR products that have lower gross margins than our legacy and truSculpt products. In addition,

Reduction in the quarter ended March 31, 2017 our enlighten average selling prices were negatively impacted due to the offering of favorable discounted pricing to our installed base of customers to upgrade to enlighten III as part of our normal market seeding of our product with key opinion leaders interested to act as future reference sites; and

Reduction in margins due to increased warranty related expenses for some of ourthe Company’s system platforms that are more complex and have a higher material cost than ourthe Company’s legacy products.

 

Sales and Marketing

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Sales and marketing

 $12,787   19

%

 $10,712  $23,560   21

%

 $19,428  $15,535   21

%

 $12,787  $28,623   21

%

 $23,560 

As a percentage of total net revenue

  35

%

      39

%

  36

%

      39

%

  37%

 

      35%

 

  37%

 

      36%

 

Sales and marketing expenses consist primarily of personnel expenses, expenses associated with customer-attended workshops and trade shows, post-marketing studies, advertising and advertising. Sales and marketing expenses as a percentage of revenue declined to 35% and 36% during the three and six months ended June 30, 2017, respectively, compared to 39% during the three and six months ended June 30, 2016. This improvement was due primarily to improved leverage in our sales and marketing expenses as well as an improvement in our direct sales employee productivity.training.

 

The $2.1$2.7 million increase in sales and marketing expenses during the three months ended June 30, 2017,2018, compared to the same period in 2016,2017, was due primarily to:

 

$1.41.7 million net increase in personnel related expenses, which were driven primarily by higher headcount and commissions in North America due to higher revenue;

$275,0000.3 million of stock based compensation due to higher marketing consulting services;headcount;

$190,0000.3 million of higher travel related expenses in North America, resulting from greater related activity and increased headcount; and

$163,0000.4 million of higher promotional and product demonstration expenses, primarily in North America.

 

SalesThe $5.1 million increase in sales and marketing expenses increased by $4.1 million induring the six months ended June 30, 2017,2018, compared to the same period in the prior year,2017, was due primarily to:

 

$2.62.8 million net increase in personnel related expenses, which were driven primarily by higher headcount and commissions in North America due to higher revenue;

$500,0000.5 million of stock based compensation due to higher promotional and product demonstration expenses, primarily in North America;headcount;

$454,0000.7 million of higher travel related expenses in North America, resulting from greater related activity and increased headcount; and

$389,0001.1 million of higher marketing consulting services.promotional and product demonstration expenses, primarily in North America.

25

 

Research and Development ((“R&D&D”)

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Research and development

 $2,981   10

%

 $2,712  $5,926   9

%

 $5,421  $4,095   37%

 

 $2,981  $7,651   29%

 

 $5,926 

As a percentage of total net revenue

  8

%

      10

%

  9

%

      11

%

  10%

 

      8%

 

  10%

 

      9%

 

R&D expenses consist primarily of personnel expenses, clinical research,, regulatory and material costs. R&D expenses increased by $269,000,$1.1 million or 37%, and represented 8%10% of total net revenue, in the three months ended June 30, 2017,2018, compared to 10%8% of total net revenue for the same period in 2016.2017. This increase in expense was due primarily to:to $1.1 million of increased personnel and consulting related expenses.

$164,000 of increased personnel and consulting related expenses.

 

R&D expenses increased by $505,000,$1.7 million or 29%, and represented 9%10% of total net revenue, in the six months ended June 30, 2017,2018, compared to 11%9% of total net revenue for the same period in 2016.2017. This increase in expense was due primarily to:to $1.7 million of increased personnel (including $0.6 million of stock-based compensation, due to headcount increase) and consulting related expenses.

$413,000 of increased personnel and consulting related expenses.

 

General and Administrative ((“G&A&A”)

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2016

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

General and administrative

 $3,548   (11

)%

 $3,997  $6,764   (6

)%

 $7,217  $4,902   38%

 

 $3,548  $10,341   53%

 

 $6,764 

As a percentage of total net revenue

  10

%

      14

%

  10

%

      14

%

  12%

 

      10%

 

  13%

 

      10%

 

 


G&A expenses consist primarily of personnel expenses, legal fees, accounting, audit and tax consulting fees, and other general and administrative expenses. G&A expenses decreasedincreased by $449,000$1.4 million or 38%, and represented 10%12% of total net revenue in the three months ended June 30, 2017,2018, compared to 14%10% of total net revenue in the same period in 2016,2017, due primarily to:

Litigation settlement expenses and legal fees associated with a litigation matter settled in the second quarter of 2016, which did not recur in 2017; partially offset by

$363,000 of increased fees related to consulting services;

$218,000 of increased personnel related expenses; and

$107,000 of increased legal fees.

to $1.4 million of increased personnel related expenses, including $1.0 million of stock-based compensation, due to headcount increase.

 

G&A expenses decreasedincreased by $453,000$3.6 million, and represented 10%13% of total net revenue in the six months ended June 30, 2017,2018, compared to 14%10% of total net revenue in the same period in 2016,2017, due primarily to:

 

Litigation settlement expenses and legal fees associated with a litigation matter settled in the second quarter of 2016, which did not recur in 2017; partially offset by

$417,0001.5 million of increased fees related to professional fees and consulting services;

$139,0001.8 million of increased personnel related expenses; andstock based compensation due to headcount increase;

$114,0000.2 million of increased other personnel related expenses due to headcount increase; and

$0.1 million of increased legal fees.

 

Interest and Other Income (expense), Net

Interest and other income, net,, consists of the following:

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

 

Interest income

 $124   59

%

 $78  $243   57

%

 $155 

Other income (expense), net

  152   9

%

  139   306   49

%

  206 

Total interest and other income, net

 $276   27

%

 $217  $549   52

%

 $361 
  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Total interest and other income (expense), net

 $(129)  (147)%

 

 $276  $(31)   (106)%

 

 $549 
As a percentage of total net revenue  0%       1%   0%       1% 

                   

Interest and other income, net, increased $59,000decreased $405,000 or (147)% and $580,000 or (106)%, respectively, in the three and six months ended June 30, 2017,2018, compared to the same period in 2016.2017. This increasedecrease was due primarily to an increase in interest income from our marketable investments resulting from an increased investment balance as well as higher rates of return.

Interest and other income, net, increased $188,000 in the six months ended June 30, 2017, compared to the same period in 2016. This increase was due primarily to a reduction in net foreign exchange losses as well as an increasea decrease in interest income from ourthe Company’s marketable investments resulting from an increaseda decrease in the investment balance as well as higher ratesbalance.

26

Provision for Income Taxes

 

 

Three Months Ended June 30,

  

Six Months Ended June 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

% Change

  

2016

  

2017

  

% Change

  

2016

  

2018

  

% Change

  

2017

  

2018

  

% Change

  

2017

 

Income (loss) before income taxes

 $2,006   267

%

 $(1,199

)

 $866   127

%

 $(3,226

)

 $(2,284)   (214)%

 

 $2,006  $(6,935)   (901)%

 

 $866 

Provision for income taxes

  59   97

%

  30   (59

)

  (209

)%

  54 

Provision (benefit) for income taxes

  (712)   (1,307)%

 

  59   (3,331)   5,546%

 

  (59) 

For the three months ended June 30, 2017, our income tax expense was $59,000, compared to $30,000 in the same period in 2016. For theand six months ended June 30, 2017, our2018, the Company’s income tax benefit was $59,000,benefits were $712,000 and $3,331,000, compared to aincome tax expense of $54,000$59,000 and income tax benefits of $59,000 in the same periodperiods in 2016.

2017. In the three and six months ended June 30, 2017, we2018, the Company calculated the provision for income taxes for interim reporting periods by applying an estimate of the ‘annual"annual effective tax rate’rate" for the full fiscal year to ordinary income or loss. Ourloss for the reporting period. The Company’s income tax benefit for the three and six months ended June 30, 2018 reflect a projected income tax benefit for U.S. and non-U.S. operations resulting in an annual effective tax rate applied to the year-to-date ordinary loss. The income tax benefit includes excess tax benefits generated by stock deductions exercised or vested in the three and six months ended June 30, 2018.

The income tax provision (benefit) for the three and six months ended June 30, 2017 related primarily to U.S. alternative minimum taxes as we arethe Company was able to utilize ourthe net operating losses brought forward against ourthe Company’s projected income for fiscal year 2017. In addition, wethe Company recorded discretely the net tax benefit of excess equity compensation costs (“windfalls”) of approximately $59,000 and $110,000 in the three and six months ended June 30, 2017, respectively.

 

For our income tax provision in the three and six months ended June 30, 2016, the tax expense was primarily related to income taxes of our non-U.S. operations as our U.S. operations were in a loss position and we had a 100% valuation allowance against them. We did not record a year-to-date tax benefit associated with the projected 2016 U.S. tax expense due to historical losses and uncertainties related to the projected income. We continue to maintain a 100% valuation allowance against our U.S. deferred tax assets in fiscal 2016 and 2017.

Due to the uncertainty regarding the timing and extent of our future profitability, we continue to record a full valuation allowance to offset our U.S. deferred tax assets, which primarily represent future income tax benefits associated with our operating losses because we do not currently believe that the positive evidence outweighs the negative evidence.  In the near future, if we conclude that sufficient positive evidence (including our estimate of future taxable income) exists to support a reversal of all or a portion of the valuation allowance, we expect that a significant portion of any release of the valuation allowance will be recorded as an income tax benefit at the time of release. In addition, as and when we discontinue recording a valuation allowance against our deferred tax assets, we expect that our income tax expense recorded in future quarters will increase.


Liquidity and Capital Resources

 

Liquidity is the measurement of ourthe Company’s ability to meet potential cash requirements, fund the planned expansion of ourthe Company’s operations and acquire businesses. OurThe Company’s sources of cash include operating activities,operations, sales and maturity of marketable investments, stock option exercises,, Employee Stock Purchase Plan contributions, and the liquidation of marketable investments. Weemployee stock purchases. The Company actively manage ourmanages the cash usage and investment of liquid cash to ensure the maintenance of sufficient funds to meet ourthe Company’s daily needs. The majority of ourthe Company’s cash and investments are held in U.S. banks and ourthe Company’s foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short-term operating expenses.

 

At June 30, 2018 and December 31, 2017, the Company had $41.2 million and $45.1 million of working capital, respectively, and the Company’s cash and cash equivalents and marketable investments totaled $29.0 million and $35.9 million as of June 30, 2018 and December 31, 2017 respectively. The Company’s combined cash and cash equivalents and marketable investments balance decreased by $6.9 million for the six months ended June 30, 2018 principally due to the settlement of accounts payable, accrued liabilities, increased inventory purchases related to the increasing demand of the Company’s products, and an increase in investments in sales, service and other management headcount to facilitate continued revenue expansion. The following table summarizes the Company’s cash and cash equivalents and marketable investments:

Cash,, Cash Equivalents and Marketable Investments

 

The following table summarizes our cash, cash equivalents, marketable investments and restricted investments:

 

(Dollars in thousands)

 

June 30,
2017

  

December 31,

2016

  

Change

  

June 30,
2018

  

December 31,

2017

  

Change

 

Cash and cash equivalents

 $18,679  $13,775  $4,904  $18,432  $14,184  $4,248 

Marketable investments

  32,270   40,299   (8,029

)

  10,573   21,728   (11,155)

 

Restricted investments

  2,290   -   2,290 

Total

 $53,239  $54,074  $(835

)

 $29,005  $35,912  $(6,907)

 

 

Cash Flows

 

 

Six Months Ended June 30,

  

Six Months Ended June 30,

 

(Dollars in thousands)

 

2017

  

2016

  

2018

  

2017

 

Net cash flow provided by (used in):

                

Operating activities

 $3,890  $(4,352

)

 $(6,503)  $3,890 

Investing activities

  5,533   1,502   10,611   5,533 

Financing activities

  (4,519

)

  (598

)

  140   (4,519) 

Net decrease in cash and cash equivalents

 $4,904  $(3,448

)

Net increase in cash and cash equivalents

 $4,248  $4,904 

27

 

Cash Flows from Operating Activities

Net cash generated fromused in operating activities was $6.5 million in the six months ended June 30, 2018, which was due primarily to:

$3.6 million net loss as adjusted for non-cash related items consisting primarily of stock-based compensation expense of $3.9 million, income tax benefit of $3.3 million, $0.5 million provision for doubtful accounts receivable, and $1.4 million depreciation and amortization expenses;

$3.7 million generated from an increase in accounts payable due primarily to increased material purchases;

$4.3 million cash used to decrease accrued liabilities;

$2.2 million cash used to increase pre-paid expenses and other long term assets.;

$1.8 million used as a result of increased accounts receivables;

$1.4 million used to increase inventories; and

$0.5 million generated from an increase in deferred revenue.

Net cash provided by operating activities was $3.9 million in the six months ended June 30, 2017, was $3.9 million, which was due primarily to:

 

$4.0 million generated due to the net income of $925,000 increased by non-cash related items of $3.1 million consisting primarily of stock-based compensation expense of $2.6 million and depreciation and amortization expenses of $492,000;

$1.7 million generated from an increase in accounts payable due primarily to increased material purchases;

$1.5 million generated from an increase in accrued liabilities due primarily to higher personnel and warranty costs;costs; and

$784,0000.8 million generated from an increase in deferred revenue; partially offset by

$1.9 million used to increase inventories;

$1.6 million used as a result of increased accounts receivables; and

$545,0000.5 million used to increase pre-paid expenses.

Net cash used in operating activities in the six months ended June 30, 2016 was $4.4 million, which was due primarily to:

$777,000 used due to the net loss of $3.3 million reduced by non-cash related items of $2.5 million consisting primarily of stock-based compensation expense of $2.1 million and depreciation and amortization expenses of $484,000;

$2.6 million used to increase inventories;

$861,000 used to increase pre-paid expenses;

$773,000 used to pay down the high year-end accrued liabilities balance;

$321,000 used by a decrease in deferred revenue; partially offset by

$793,000 generated from an increase in accounts payable; and

$464,000 generated from the collection of cash from the seasonally high accounts receivable balance as of December 31, 2015.


 

Cash Flows from Investing Activities

We generated netNet cash provided by investing activities was $10.6 million in the six months ended June 30, 2018, which was attributable primarily to:

$15.5 million in net proceeds from the sales and maturities of marketable investments; partially offset by

$4.4 million of cash used to purchase marketable investments; and

$0.6 million of cash used to purchase property, equipment and software.

Net cash provided by investing activities was $5.5 million in our investing activities in the six months ended June 30, 2017, which was attributable primarily to:

 

     $31.6 million in net proceeds from the sales and maturities of marketable investments; partially offset by

●     $25.9 million of cash used to purchase marketable investments; and

●     $210,000 of cash used to purchase property, equipment and software.

We generated net cash of $1.5 million in our investing activities in the six months ended June 30, 2016, which was attributable primarily to:

●     $15.6 million in net proceeds from the sales and maturities of marketable investments; partially offset by

●     $14.0 million of cash used to purchase marketable investments; and

●     $137,000 of cash used to purchase property, equipment and software.

$31.6 million in net proceeds from the sales and maturities of marketable investments; partially offset by

$25.9 million of cash used to purchase marketable investments; and

$0.2 million of cash used to purchase property, equipment and software.

 

Cash Flows from Financing Activities

Net cash provided by financing activities was $140,000 in the six months ended June 30, 2018, which was primarily due to:

$3.0 million proceeds from exercise of stock options and employee stock purchase plan, offset by

$2.7 million of cash used for taxes paid related to net share settlement of equity awards; and

$0.2 million of cash used to pay capital lease obligations.

Net cash used in financing activities was $4.5 million in the six months ended June 30, 2017, which was primarily due to:

 

$7.0 million used to repurchase common stock;

$1.2 million of cash used for taxes paid related to net share settlement of equity awards;

$182,0000.2 million used to pay down our capital lease obligations of $182,000;obligations; partially offset by

$3.9 million of cash generatedproceeds from the issuanceexercise of common stock due to employees exercising their stock options and purchasingemployee stock through the ESPP program.

Net cash used in financing activities was $598,000 in the six months ended June 30, 2016, which was primarily due to:

$2.9 million used to repurchase common stock;

$556,000 of cash used for taxes paid related to net share settlement of equity awards; partially offset by

$3.0 million generated from the issuance of common stock due to employees exercising their stock options and purchasing stock through the ESPP program.purchase plan.

 

AdequacyAdequacy of Cash Resources to Meet Future Needs

Cash Resources to Meet Future Needs

WeThe Company had cash, cash equivalents, and marketable investments of $50.9$29.0 million as of June 30, 2017.2018. For the first six months of 2017, we financed our operations through our operating activities,2018, the salesCompany’s principal source of liquidity is cash from maturity and maturitiessales of marketable investments and cash generated from the sale ofissuance of common stock due to employees exercising theirthrough exercise of stock options and the Company’s employee stock purchasing stock through the ESPP program. In July 2017, our Board of Directors approved an incremental $25.0 million to be added to the $3.1 millionThe Company believes that was available to repurchase stock as of June 30, 2017.  We believe the existing capitalcash resources including cash, cash equivalents and investments of $53.2 million, are sufficient to meet our operatingthe Company’s anticipated cash needs for working capital and capital requirementsexpenditures for at least the next several years,years.

28

Loan and enable us to repurchase stock pursuant to our Share Repurchase Program.  Security Agreement

 

In July 2017, we terminatedOn May 30, 2018, the building lease for a new facility in Fremont, California, that we hadCompany and Wells Fargo Bank, N.A. (“Wells Fargo”) entered into a Loan and Security Agreement (the “Revolving Line of Credit”) in the original principal amount of $25,000,000. The Revolving Line of Credit terminates on May 2017. In conjunction30, 2021. The purpose of the Revolving Line of Credit is to provide working capital and to fund the Company’s general business requirements. The Revolving Line of Credit bears interest at a variable interest rate equal to the LIBOR Rate plus a defined LIBOR Rate Margin based on the then-current Leverage Ratio (a ratio of funded debt to the Trailing Twelve Month ("TTM") Adjusted EBITDA).

The Revolving Line of Credit provides for borrowing limits that range from $5,000,000 to a maximum of $25,000,000 during the term of the Revolving Line of Credit. Additionally, the Company agrees to pay a variable unused commitment fee to Wells Fargo equal to (a) 0.25% per annum if the Leverage Ratio is less than 1.00 to 1.00, (b) 0.30% per annum if the Leverage Ratio is equal to or greater than 1.00 to 1.00, but less than 2.00 to 1.00, and (c) 0.35% per annum if the Leverage Ratio is equal to or greater than 2.00 to 1.00.

The Revolving Line of Credit is secured by a pledge of security interest in all the shares of each material subsidiary, together with this lease termination, we receivedall proceeds, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted, and all other cash and noncash proceeds, as security for the performance of the Obligations. As of June 30, 2018, there were no borrowings under the Revolving Line of Credit.

Covenants 

The Loan and Security Agreement contains financial and other covenants as well as the maintenance of a lump sum termination paymentleverage ratio not to exceed 2.5:1.0 and a TTM adjusted EBITDA not less than $10 million. A violation of $4.0 million fromany of the landlord. In addition, we cancelledcovenants could result in a standby letterdefault under the Loan and Security Agreement that would permit the lenders to restrict the Company’s ability to further access the revolving line of credit that we had providedfor loans and letters of credit and require the landlord as a security deposit, which removed all restrictions on $2.3 million of investments that were used to secure the letter of credit. Except for the foregoing, cash used to fund our operating activities in certain historical quarters, purchase fixed assets and repurchase our common stock, we are unawareimmediate repayment of any other known trends or any known demands, commitments, events or uncertainties, including collectabilityoutstanding loans under the Loan and Security Agreement. As of our accounts receivable, that will resultJune 30, 2018, the Company is in or that are reasonably likely to result in, liquidity increasing or decreasing in any material way.compliance with all financial covenants.

 

Commitments and Contingencies

There have beenDuring the six months ended June 30, 2018, there were no material changes to ourthe Company’s commitments and contingencies from those discloseddescribed under Management’s Discussion and Analysis of Financial Condition and Results of Operations in ourthe Annual Report on Form 10-K10-K for the year ended December 31, 2016,2017, filed with the SEC on March 15, 2017.26, 2018.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

A summary of the key market risks facing the Company is disclosed below. For a detailed discussion, please see ourthe Company’s Annual Report on Form 10-K for the year ended December 31, 2016,2017, filed with the SEC on March 15, 2017.26, 2018.

 

Interest Rate Fluctuations:Fluctuations

Our exposure to interest rate risk relates primarily to ourThe Company holds cash equivalents as well as short-term and long-term fixed income securities. The Company’s investment portfolio which includes primarily debt instruments offixed and floating rate securities. Changes in interest rates could impact the U.S. Government and its agencies, municipal bonds, corporate debt securities and commercial paper.Company’s anticipated interest income. Fixed rate securities may have their fair market value adversely impacted if there is an increasedue to fluctuations in interest rates. While it is our intentrates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to hold these securitiesfactors, the Company’s future investment income may fall short of expectation due to maturity,changes in interest rates or we may suffer losses in principal if for some reason we needforced to sell a security that hassecurities which have declined in market value due to changes in interest rates, thenrates. The primary objective of the Company’s investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we may suffer lossesinvest in principal.debt instruments of the U.S. Government and its agencies and municipal bonds, high grade corporate bonds, commercial paper, CDs and money markets, and, by policy, restrict the Company’s exposure to any single type of investment or issuer by imposing concentration limits. To minimize the exposure due to adverse shifts in interest rates, we maintain investments at a weighted average maturity of generally less than eighteen months. Based

As at June 30, 2018, the Company had not drawn on discounted cash flow modeling with respectthe Revolving Line of Credit. Overall interest rate sensitivity is primarily influenced by any amount borrowed on the line of credit and the prevailing interest rate on the line of credit facility. The effective interest rate on the line of credit facility is based on a floating per annum rate equal to our total investment portfoliothe LIBOR rate. The LIBOR rate was 2.09% as of June 30, 2017, assuming a hypothetical2018, and accordingly the Company may incur additional expenses if the Company has an outstanding balance on the line of credit and the LIBOR rate increase in interest rates of one percentage point (or 100 basis points), the fair value of our total investment portfolio would have potentially declined by approximately $134,000.future periods.

 


Inflation

The Company does not believe that inflation has had a material effect on the Company’s business, financial condition, or results of operations. If the Company’s costs were to become subject to significant inflationary pressures, the Company may not be able to fully offset such higher costs through price increases. The Company’s inability or failure to do so could harm the Company’s business, financial condition, and results of operations.

 

Foreign Exchange Fluctuations:Fluctuations

We do not actively hedge our exposure to currency rate fluctuations. AlthoughThe Company generates revenue in Japanese Yen, Euros, Australian Dollars, Canadian Dollars, British Pounds and Swiss Francs. Additionally, a significant proportionportion of our revenuethe Company’s operating expenses and costsassets and liabilities are denominated in each of these currencies. Therefore, fluctuations in these currencies against the U.S. Dollars, we are exposeddollar could materially and adversely affect the Company’s results of operations upon translation of the Company’s revenue denominated in these currencies, as well as the remeasurement of the Company’s international subsidiaries’ financial statements into U.S. dollars.

The Company has historically not engaged in hedging activities relating to the Company’s foreign currency fluctuations in countries where we havedenominated transactions, given the Company has a direct operation. The three major currencies that we have exposurenatural hedge resulting from the Company’s foreign cash receipts being utilized to and have assets and liabilities denominated infund the respective local currencies in, are Japanese Yen, Euro and Australian Dollar.currency expenses.

29

 

ITEM 4.CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

An evaluation as of June 30, 2018 was carried out under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of the Company’s “disclosure controls and procedures.” Rule 13a-15(e) under the Exchange Act defines “disclosure controls and procedures” as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures were effective at June 30, 2018.

 

Attached as exhibits to this Quarterly Report are certifications of our Chief Executive Officer (“CEO”)the Company’s CEO and Chief Financial Officer (“CFO”),CFO, which are required in accordance with Rule 13a-14 of the Securities Exchange Act of 1934, as amended (“Exchange Act”).Act. This Controls and Procedures section includes the information concerning the controls evaluation referred to in the certifications, and it should be read in conjunction with the certifications for a more complete understanding of the topics presented.

We conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures (as defined in the Rules 13a-15(e) and 15d-15(e) under the Exchange Act) (“Disclosure Controls”) as of the end of the period covered by this Report required by Exchange Act Rules 13a-15(b) or 15d-15(b). The controls evaluation was conducted under the supervision and with the participation of our management, including the CEO and CFO. Based on this evaluation, the CEO and CFO have concluded that as of the end of the period covered by this report the disclosure controls and procedures were effective at a reasonable assurance level.

 

Definition of Disclosure ControlsChanges in Internal Control over Financial Reporting

Disclosure Controls are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized and reported within the time periods specifiedThere were no changes in the SEC’s rules and forms. Disclosure Controls are also designed to reasonably assure that such information is accumulated and communicated to our management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Our Disclosure Controls include components ofCompany’s internal control over financial reporting which consists of control processes designedthat occurred the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to provide reasonable assurance regardingmaterially affect, the reliability of its financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the U.S. To the extent that components of ourCompany’s internal control over financial reporting are included within Disclosure Controls, they are included in the scope of our annual controls evaluation.reporting.

 

LimitationsLimitations on the Effectiveness of Controls

Our management, including the CEO and CFO, does not expect that our disclosure controls or internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed andconceived and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further,of the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, and instances of fraud, if any, within a company have been detected. These inherent limitations includeAccordingly, the realitiesCompany’s disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overrideobjectives of the controls. The designCompany’s disclosure control system are met. As set forth above, the Company’s Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of any systemthe end of the period covered by this report, that the Company’s disclosure controls is based in part on certain assumptions about the likelihood of future events, and there can be noprocedures were effective to provide reasonable assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Becauseobjectives of the inherent limitations in a cost-effectiveCompany’s disclosure control system misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.met.

 


30

 

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

 

We are named from

ITEM 1.        LEGAL PROCEEDINGS

From time to time, asthe Company may be involved in legal and administrative proceedings and claims of various types. For a partydescription of the Company’s material pending legal and regulatory proceedings and settlements refer to product liabilityNote 12 to the Company’s consolidated financial statements entitled “Litigation and contractual lawsuitsRelated Matters,” in the normal course of business. We routinely assessAnnual Report on Form 10-K for the likelihood of any adverse judgments or outcomes related to legal matters and claims, as well as ranges of probable losses. A determination ofyear ended December 31, 2017, filed with the amount of the reserves required, if any, for these contingencies is made after analysis of each known issue, historical experience, whether it is more likely than not that we shall incur a loss, and whether the loss is estimable. We are not currently a party to any material legal proceedings.SEC on March 26, 2018.

ITEM 1A.

RISK FACTORS

 

OurITEM 1A.     RISK FACTORS

The Company’s business faces many risks. Any of the risks referenced below or elsewhere in this Report on Form 10-Q or ourthe Company’s other SEC filings could have a material impact on ourthe Company’s business and consolidated financial position or results of operations. Additional risks and uncertainties not presently known to usthe Company or that wethe Company currently believebelieves to be immaterial may also impair ourthe Company’s business operations.

 

There have been no material changes in the risk factors set forth in Part I, Item 1A, "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. For additional detailed discussion of risk factors that should be understood by any investor contemplating investment in ourthe Company’s stock, please refer to “Part I.Part I, Item 1A. Risk Factors”1A, "Risk Factors" in our 2016 Form 10-K and elsewhere as described in thisthe Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 26, 2018 and elsewhere in this Form 10-Q.

Our failure to attract and retain qualified personnel and any changes in our key personnel, including officers, could adversely affect our operations.

Our employees are vital to our success and our ability to grow in the future will depend upon our ability to attract, hire and retain highly qualified employees. On April 17, 2017, we announced the resignation of Ronald J. Santilli, our Executive Vice President and Chief Financial Officer, effective following a transition period once his successor is named. On July 12, 2017 we announced the retention of Sandra A. Gardiner as Chief Financial Officer on a consulting basis as the Company continues a search for a permanent CFO.  We are currently engaged in an ongoing effort to identify and hire a successor. We believe that we have thus far been successful in attracting and retaining qualified personnel in a highly-competitive labor market due, in large part, to our competitive compensation and benefits and our rewarding work environment, and providing employees with opportunities to contribute to our continued growth and success. However, our failure to attract and retain qualified personnel and any changes in our key personnel, including officers, could adversely affect our operations.


ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The following table summarizes the activity related to stock repurchases for the six months ended June 30, 2017 (in thousands except per share data)ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS:

Period

 

Total Number
of Shares
Purchased

  

Average Price

Paid

per Share

  

Total Number of
Shares Purchased
as Part of

Publicly Announced
Plans or Programs

  

Approximate Dollar Value of Shares

That May Yet

Be Purchased

Under the Plans

or Program

 

February 21-28, 2017

  30  $21.06   30  $9,509 

March 1-31, 2017

  110   20.57   110   7,238 

April 1-30, 2017

  75   19.64   75   5,766 

May 1-30, 2017

  44   20.29   44   4,866 

June 1-30, 2017

  75   23.55   75   3,110 

February 21-June 30, 2017

  334  $21.03   334  $3,110 

As of December 31, 2016, we had $5.1 million available in our Stock Repurchase Program. On February 13, 2017 our Board of Directors approved an additional $5 million to be added to the program.

 

In the six months ended June 30, 2017, we repurchased 334,244 shares of our common stock for approximately $7.0 million. As of June 30, 2017, there remained an additional $3.1 million available in the Stock Repurchase Program to repurchase shares of common stock. All shares repurchased were retired and returned to authorized but unissued status.None.

On July 28, 2017 our Board of Directors approved an incremental $25 million to be added to the Stock Repurchase Program.

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES

DEFAULTS UPON SENIOR SECURITIES

 

None.

ITEM 4.

MINE SAFETY DISCLOSURES

 

None.ITEM 4.        MINE SAFETY DISCLOSURES

 

None.

ITEM 5.        OTHER INFORMATION

OTHER INFORMATION

 

None.

 


31

 

ITEM 6.EXHIBITS

 

Exhibit No.

 

Description

3.2    3.1

(1)  

Amended and Restated Certificate of Incorporation of the Registrant (Delaware).(filed as Exhibit 3.5 to our Quarterly Report on Form 10-Q filed on November 7, 2017 and incorporated herein by reference)

3.2

  

3.4

(1)

Bylaws of the Registrant.

3.5(3)Second AmendedRegistrant (filed as Exhibit 3.4 to our Current Report on Form 8-K filed on January 8, 2015 and Restated Certificate of Incorporation of the Registrant (Delaware).
incorporated herein by reference)

4.1

(2)  

Specimen Common Stock certificate of the Registrant.Registrant (filed as Exhibit 4.1 to our Annual Report on Form 10-K filed on March 25, 2005 and incorporated herein by reference)

10.18

  

10.24(4)

6530 Paseo Padre Parkway Fremont, California Lease dated May 2, 2017Loan and Security Agreement in the original principal amount of $25,000,000 by and between the Company and SI 28, LLC.

10.25(3)Cutera, Inc. 2004 Amendedin favor of Wells Fargo Bank, N.A. effective May 30, 2018 (filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 4, 2018 and Restated Equity Incentive Plan.
10.26(5)6530 Paseo Padre Parkway Fremont, California Lease Termination Agreement dated July 6, 2017incorporated herein by and between the Company and SI 28, LLC.
10.27(5)Second Amendment to Brisbane Technology Park Lease dated July 6, 2017 by and between the Company and BMR-Bayshore Boulevard LP.
reference)

31.1

 

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

2002

31.2

  

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

2002

32.1

 

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.CU.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.2002

101.INS

 

101.ins

XBRL Instance Document

101.sch101.SCH

 

XBRL Taxonomy Extension Schema Document

101.cal101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

101.def101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

101.lab101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

101.pre101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

(1)

Incorporated by reference from our Registration Statement on Form S-1 (Registration No. 333-111928) which was declared effective on March 30, 2004.

(2)

Incorporated by reference from our Annual Report on Form 10-K filed with the SEC on March 25, 2005.

(3)

Incorporated by reference from our Definitive Proxy Statement on Form 14A filed with the SEC on May 1, 2017.

(4)
Incorporated by reference from Current Report on From 8-K filed May 9, 2017.
Incorporated by reference from Current Report of From 8-K filed May 9, 2017.
(5)Filed herewith.

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of The Securities Exchange Act of 1934, the registrant has duly caused this reportreport to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Brisbane, State of California, on the 7th day of August, 2017.2018.

 

 

CUTERA, INC.

 

 

 

/S/SANDRAA.GARDINER

 

Sandra A. Gardiner

ExecutiveVicePresidentandChiefFinancialOfficer

(PrincipalFinancialandAccountingOfficer)

Consultant Chief Financial Officer

(Principal Financial and Accounting Officer)

 

2532